Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

Jean-Guy Baril1 *, Jonathan B. Angel2, M. John Gill3, Joseph Gathe4, Pedro Cahn5, Jean van Wyk6, Sharon Walmsley7,8

1 Clinique médicale du Quartier latin, Montreal, Quebec, Canada, 2 Division of Infectious Diseases, University of Ottawa and the Ottawa Hospital, Ottawa, Ontario, Canada, 3 Department of Medicine, University of Calgary, Calgary, Alberta, Canada, 4 Therapeutic Concepts, Houston, Texas, United States of America, 5 Fundación Huesped, Buenos Aires, Argentina, 6 AbbVie Inc., North Chicago, Illinois, United States of America, 7 Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada, 8 University of Toronto, Toronto, Ontario, Canada

* jgbaril@videotron.ca

Abstract

Objective
We reviewed the current literature regarding antiretroviral (ARV)-sparing therapy strategies to determine whether these novel regimens can be considered appropriate alternatives to standard regimens for the initial treatment of ARV-naive patients or as switch therapy for those patients with virologically suppressed HIV infection.

Methods
A search for studies related to HIV dual therapy published from January 2000 through April 2014 was performed using Biosis, Derwent Drug File, Embase, International Pharmaceutical Abstracts, Medline, Pascal, SciSearch, and TOXNET databases; seven major trial registries, and the abstracts of major conferences. Using predetermined criteria for inclusion, an expert review committee critically reviewed and qualitatively evaluated all identified trials for efficacy and safety results and potential limitations.

Results
Sixteen studies of dual therapy regimens were critiqued for the ARV-naive population. Studies of a protease inhibitor/ritonavir in combination with the integrase inhibitor raltegravir or the nucleoside reverse transcriptase inhibitor lamivudine provided the most definitive evidence supporting a role for dual therapy. In particular, lopinavir/ritonavir or darunavir/ritonavir combined with raltegravir and lopinavir/ritonavir combined with lamivudine demonstrated...
noninferiority to standard of care triple therapy after 48 weeks of treatment. Thirteen trials were critiqued in ARV-experienced, virologically suppressed patients. The virologic efficacy outcomes were mixed. Although overall data regarding toxicity are limited, when compared with standard triple therapy, certain dual therapy regimens may offer advantages in renal function, bone mineral density, and limb fat changes; however, some dual combinations may elevate lipid or bilirubin levels.

Conclusions

The potential benefits of dual therapy regimens include reduced toxicity, improved tolerability and adherence, and reduced cost. Although the data reviewed here provide valuable insights into the effectiveness and tolerability of dual therapy regimens, it remains unclear whether these potential benefits can be maintained long-term. Appropriately powered studies with longer follow-up periods are needed to more definitively assess potential toxicity reduction advantages with dual therapy.

Introduction

In the late 1980s/early 1990s, the sequential use of nucleoside reverse transcriptase inhibitor (NRTI) monotherapy and dual therapies in patients with HIV infection rapidly led to treatment failure because of the emergence of resistance-associated mutations [1]. The use of combination antiretroviral therapy (cART) began in the mid-1990s, in which 2 NRTIs were combined with a third agent from a different therapeutic class. Current treatment guidelines continue the convention of preferred cART based on combining a dual NRTI backbone with a “third anchor” agent, such as a ritonavir (r)-boosted protease inhibitor (PI; PI/r), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor [2–4]. The toxicities associated with long-term use of NRTIs have led to the assessment of dual therapy approaches that do not include an NRTI component. A higher risk of treatment failure was observed in early NRTI-sparing studies compared with current standard triple therapy regimens [5–7].

Cohort studies suggest that patients with HIV are now living longer and are encountering an increased prevalence of comorbidities associated with natural aging, including renal, cardiovascular, or liver diseases; cognitive decline; metabolic disorders (diabetes and dyslipidaemia); and osteoporosis [8,9]. Drug-related adverse events (AEs) associated with the long-term use of antiretroviral therapy (ARV) may contribute to these comorbidities [10–13].

With the improved potency, tolerability, and durability of newer drugs and the higher barrier to the development of resistance, interest has re-emerged for ARV-sparing strategies, including monotherapy and dual therapies. These strategies have been applied as initial therapy in ARV-naive patients or as a switch strategy in those patients who have become virologically suppressed on standard regimens. Ideally, these regimens should achieve and maintain viral suppression and immunologic control while minimizing short- and long-term AEs, improve adherence and convenience, and reduce costs.

One well-studied therapeutic approach is the use of PI/r monotherapy following suppression with standard triple therapy. Although successful for a majority of patients, PI monotherapy was found to be associated with a statistically significant increased risk of virologic failure and an increased incidence of PI-associated resistance [14]. Although most failures were re-suppressed by reinitiating NRTI therapies, this strategy is reserved for special circumstances.
Current guidelines do not include dual therapy regimens as a standard treatment strategy unless specific clinical characteristics (e.g., comorbidities, pre-treatment viral load, and CD4 cell counts) of the individual patient warrant their use [2–4].

The objective of this report was to summarise data in the published literature regarding dual therapy approaches for treating ARV-naive patients and as a switch strategy for virologically suppressed patients on ARV therapy. We reviewed the literature from January 2000, with the approval of the first PI/r, until April 2014, in order to evaluate the efficacy of dual therapy regimens and the on long-term safety, AEs, and comorbidities associated with these regimens.

Methods

PRISMA guidelines for reporting systematic reviews were followed. The checklist is available as deroiting information (S1 PRISMA Checklist).

Search Strategy

ProQuest Dialog, Biosis, Derwent Drug File, Embase, International Pharmaceutical Abstracts, Medline, Pascal, and SciSearch databases were searched from January 2000 through April 2014 for studies related to HIV dual therapy. TOXNET was searched for AEs. Subject headings and keywords were tailored for each electronic resource using the following concepts: (atazanavir OR darunavir OR dolutegravir OR fosamprenavir OR indinavir OR lopinavir OR saquinavir) AND (efavirenz OR enfuvirtide OR etravirine OR lamivudine OR maraviroc OR nevirapine OR raltegravir OR rilpivirine OR saquinavir OR tenofovir OR tipranavir). The term “HIV dual therapy” was searched separately to capture potential combinations not explicitly stated above. The CRD/Cochrane Highly Sensitive Search Strategy [15] was used to restrict the research to randomised controlled trials in PubMed. For conference proceedings, we searched NLM Gateway (2008–2010); International AIDS Society Conference on HIV Pathogenesis and Treatment and Prevention (WAC/IAS) 2009–2013; Conference on Retroviruses and Opportunistic Infections (CROI) 2009–2014; International Congress on Drug Therapy in HIV Infection 2008, 2010, and 2012 (JIAS); International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV 2009–2012; European AIDS Clinical Society (EACS) 2009, 2011, and 2013; and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009–2013. Data were extracted from published abstracts or posters and oral presentations, where available. The following trial registries were searched for ongoing studies: Citeline’s TrialTrove, ClinicalTrials.gov, EuDRA, ANZCTR, Nederlands Trial Register, International Clinical Trials Registry Platform (ICTRP), and the International Federation of Pharmaceutical Manufacturers & Associations. We reviewed all identified trials and determined their suitability for inclusion.

Eligibility Criteria

Eligible studies included randomised controlled or prospectively designed trials evaluating dual therapy combinations with a protease inhibitor (with or without r boosting [PI/r and PI, respectively]), an integrase inhibitor, an NNRTI, a CCR5 inhibitor, or lamivudine. A minimum 24-week duration of treatment in adults with HIV-1 infection who were ARV-naive or were switched after being virologically suppressed was required. Pilot/proof-of-concept studies and studies presented only as abstracts, which may not have been adequately powered, were also considered for inclusion. Case reports, reviews, correspondence, and research letters were excluded, as were phase 1, laboratory, pharmacokinetic/pharmacodynamic, prevention of vertical transmission, and retrospective studies or those including patients who were ARV-experienced but not suppressed, pediatric, or pregnant or patients who had a coinfection.
A primary outcome of suppression of viral load, change in viral load, or virologic failure (VF) was assessed; other outcomes were acceptable as a primary endpoint if they were supplemented by secondary endpoints that included the aforementioned criteria. Toxicity and/or comorbidity-related secondary outcomes were also evaluated.

Data Abstraction and Qualitative Data Synthesis
The primary endpoint was efficacy (achieved or maintained virologic suppression, usually defined as <50 copies mL of HIV-1 RNA). Intent-to-treat (ITT) analyses were preferentially reported; however, per-protocol or observed analyses were also permitted. Changes in CD4 cell counts, discontinuation rates and tolerability or toxicity, lipid levels, renal function, bone mineral density (BMD), and body fat redistribution were examined, whether these parameters were predefined or reviewed post hoc. Subanalyses of included studies were also examined. In the trials, patients were classified as ARV-naive or virologically suppressed, and the results were examined qualitatively based on efficacy and safety results, as well as power and other study design limitations. The study entry criteria for inclusion, endpoints (actual rates and definitions), and comparators are presented in tabular format due to the large number of studies summarised in this review (n = 29).

Results
Twenty-nine studies examining novel dual therapy regimens were included in the analysis (Fig 1); 16 trials contained ARV-naive patients and 13 had ARV-experienced, virologically suppressed patients.

Trials in ARV-Naive Patients
Sixteen trials of novel dual therapy regimens in ARV-naive patients were included; of these trials (Fig 1), many were underpowered to confirm noninferiority of the strategy relative to

---

### Records identified through searches:
- n=1292

### Did not meet inclusion criteria:
- n=1212

### Met inclusion criteria:
- n=80

### Duplicates:
- n=51

### Records included in qualitative synthesis:
- n=29

---

*Fig 1. Flow diagram of literature search for systematic review.*

doi:10.1371/journal.pone.0148231.g001
standard of care. Trial designs and key findings from these studies are summarised in Tables 1, 2 and 3 and are discussed briefly by strategy below. Virologic efficacy results are summarised in Fig 2A.

**PIs in Combination With Raltegravir**

**Atazanavir + raltegravir therapy.** The SPARTAN study [16] (a noncomparative pilot study; N = 93) compared atazanavir (ATV) + raltegravir (RAL) with ATV/r + tenofovir/emtricitabine (TDF/FTC) and was terminated early. Although the efficacy of ATV + RAL was similar to ATV/r + TDF/FTC, combination therapy with ATV + RAL was associated with a high rate of severe hyperbilirubinaemia. Despite a high dose of ATV (300 mg twice daily [BID]), the development of RAL resistance was seen in regimen failures.

**Darunavir/r + RAL therapy.** Results from studies evaluating darunavir (DRV)/r plus RAL are mixed. The RADAR study [17,18] (N = 80) provided some initial evidence for the effectiveness of DRV/r + RAL therapy; however, the 48-week results did not confirm the non-inferiority of the DRV/r + RAL arm because of a higher level of discontinuations compared with the DRV/r + TDF/FTC arm. Likewise, in ACTG A5262 [19], DRV/r + RAL therapy demonstrated poorer than expected results in this single-arm phase 2 study. Among 112 patients, HIV-RNA levels were not suppressed in 11 patients and 6 and 11 patients rebounded by weeks 24 and 48, respectively, resulting in a 26% failure rate overall [19]. Although high baseline viral loads and poor adherence could have contributed to the poor results, the lack of a comparator arm limits the assessment of these data.

The NEAT 001 study [20], a large (N = 805) noninferiority randomised open-label study comparing the efficacy and safety of DRV/r in combination with either TDF/FTC or RAL, utilized time to treatment failure (virologic or clinical) as the primary endpoint. Per Kaplan-Meier methodology, therapy failure occurred in an estimated 17.4% of patients in the RAL arm and 13.7% in the TDF/FTC arm after 96 weeks (adjusted difference, 3.7% [95% CI, −1.1 to 8.6]), falling within a pre-specified noninferiority margin of 9%. In subgroup analyses, patients with CD4 counts <200 cells/μL had substantially higher rate of treatment failures using RAL therapy compared with TDF/FTC therapy. The reasons for the less than optimal treatment response in the non-NRTI arm in this subset of patients are being studied further. Although the number of virologic failures was low, 5 patients in the RAL arm developed integrase resistance, whereas no patients in the TDF/FTC arm had with PI resistance.

**LPV/r + RAL Therapy.** In the CCTG 589 pilot trial [21] (N = 51) comparing therapy with LPV/r + RAL with efavirenz (EFV) + TDF/FTC, a high discontinuation rate (19.2%) decreased the proportion of patients who achieved viral suppression with LPV/r + RAL (69%; ITT analysis); however, by observed analysis, 86% of patients achieved HIV-1 RNA levels <50 copies/mL at 48 weeks. In the PROGRESS trial [22–25], the noninferiority of LPV/r + RAL (n = 101) to LPV/r + TDF/FTC (n = 105) was demonstrated at 48 weeks (using a 20% noninferiority margin), with 83.2% and 84.8% of patients achieving HIV-1 RNA levels <40 copies/mL, respectively (ITT analysis; difference, −1.6%; 95% CI, −12.0% to 8.8%). At week 96, 66.3% and 68.6% of patients had viral load suppression (<50 copies/mL; ITT analysis). LPV/r + RAL was generally well-tolerated [22–25].

**PIs in Combination With Maraviroc**

Four studies assessed a PI/r in combination with maraviroc (MVC). The VEMAN (N = 50) and A4001078 (N = 121) studies demonstrated virologic suppression with LPV/r + MVC and ATV/r + MVC, respectively, in ARV-naive patients [26–30]. In the A4001078 study, the grade 3 and 4 elevations in bilirubin levels in patients treated with ATV/r + MVC (36.7%) versus
### Table 1. Study designs for identified trials in ARV-naive patients.

| Regimen | Study Name | Duration | Type | Treatment Arm | Dose | Primary Endpoint |
|---------|------------|----------|------|---------------|------|------------------|
| PI/r + RAL | SPARTAN [16] | 96 weeks (planned, terminated at 24 weeks but patients receiving treatment could continue) | Multicentre, randomised, open-label, non-comparative pilot study | ATV + RAL (n = 63, 45 evaluable at week 48) | 300 mg BID + 400 mg BID | HIV-1 RNA <50 copies/mL at week 24 (ITT): 74.6% vs 63.3% |
| | | | | ATV/r + TDF/FTC (n = 30, 25 evaluable at week 48) | 300/100 mg QD + 300/200 mg QD | |
| | RADAR [17,18] | 48 weeks, on-going | Randomised, open-label, pilot | DRV/r + RAL (n = 40) | 800/100 mg QD + 400 mg BID | HIV-1 RNA <48 copies/mL at week 24 (ITT): 88.9% vs 81.0% |
| | | | | DRV/r + TDF/FTC (n = 40) | 800/100 mg QD + 245/200 mg QD | |
| | ACTG A5262 [19] | 52 weeks | Phase 2b, single-arm, open-label, multicentre | DRV/r + RAL (n = 112) | 800/100 mg QD + 400 mg BID | VF by week 24 (ITT): 16% (17 patients) |
| | NEAT001/ANRS143 [20] | 123 weeks | Phase 3, randomised, open-label, multicentre, parallel group | DRV/r + RAL (n = 401) | 800/100 mg QD + 400 mg BID | Time to treatment failure (virologic or clinical) 17.4% vs 13.7% |
| | | | | DRV/r + TDF/FTC (n = 404) | 800/100 mg QD + 245/200 mg QD | |
| | CCTG 589 [21] | 48 weeks | Randomised, open-label, pilot | LPV/r + RAL (n = 26) | Not reported | HIV-RNA <50 copies/mL, significantly higher with LPV/r + RAL at week 4 (P = 0.003) but not at week 48 |
| | | | | EFV/TDF/FTC (n = 25) | Not reported | |
| | PROGRESS [22–25] | 96 weeks | Randomised, noninferiority, open-label, multicentre | LPV/r + RAL (n = 101) | 400/100 mg QD + 400 mg BID | HIV-1 RNA <40 copies/mL at week 48 (ITT): 83.2% vs 84.8% |
| | | | | LPV/r + TDF/FTC (n = 105) | 400/100 mg QD + 300/200 mg QD | |
| PI/r + MVC | A4001078 [26,28,30] | 48 weeks, later extended to 96 weeks | Phase 2b, randomised, open-label, pilot | ATV/r + MVC (n = 60) | 300/100 mg QD + 150 mg QD | HIV-1 RNA <50 copies/mL at week 48 (ITT): 74.6% vs 83.6% |
| | | | | ATV/r + TDF/FTC (n = 61) | 300/100 mg QD + 300/200 mg QD | |
| | | | | MIDAS [31] | 48 weeks | Single-arm | DRV/r + MVC (n = 24) | 800/100 mg QD + 150 mg QD | VF (HIV-1 RNA >50 copies/mL) at week 24 or later: 12.5% at week 24; 16.7% at week 48 |
| | | | | MODERN [32] | 48 weeks | Interventional, randomised open-label | DRV/r + TDF/FTC (n = 406) | 800/100 mg QD + 300/200 QD | Trial terminated after IDMC review due to inferior efficacy of MVC arm |
| | | | | VEMAN [27,29] | 48 weeks | Prospective, randomised, open-label, proof-of-concept, multicentre | LPV/r + MVC (n = 26) | Not reported + 150 mg QD | HIV-1 RNA <50 copies/mL at week 48 (PP): 100% vs 96% |
| | | | | | LPV/r + TDF/FTC (n = 24) | Not reported | (Continued) |
| Regimen          | Study Name | Duration     | Type                              | Treatment Arm                                                                 | Dose                                   | Primary Endpoint                                                                 |
|------------------|------------|--------------|-----------------------------------|-------------------------------------------------------------------------------|----------------------------------------|----------------------------------------------------------------------------------|
| PI/r + 3TC       | Loretia    | 48 weeks     | Phase 4, single-arm, multicentre, open-label, pilot | LPV/r + 3TC (n = 39)                                                         | 400/100 mg BID + 300 mg QD             | HIV-1 RNA <48 copies/mL at week 48 (ITT): 66.7%                                  |
|                  | Loretia    | 48 weeks     | Prospective, randomised, controlled, open label, noninferiority | LPV/r + 3TC (n = 217)                                                         | 400/100 mg BID + 150 mg BID            | HIV-1 RNA <50 copies/mL at week 48 (ITT): 88.3% (dual) vs 83.7% (triple)        |
| PI/r + NNRTI     | BMS-121    | 48 weeks     | Randomised multicentre             | ATV/r + EFV (n = 32)                                                          | 300/100 mg QD + 600 mg QD             | Mean percentage change from baseline in fasting plasma TG at week 8 in the combined treatment regimens: 61% (95% CI, 43.3%--80.7%) |
|                  | Actg 5142  | Median follow-up of 112 weeks | Phase 3, randomised multicenter, open-label | EFV + LPV/r (n = 250)                                                         | 600 mg QD + 533/133 mg BID            | Time to VF: significantly longer for EFV + 2 NRTIs vs LPV/r + 2 NRTIs; and time to regimen failure: no statistically significant differences between EFV + LPV/r and other groups in time to VF |
|                  | Mediclas   | 24 months    | Multicenter, multinational, single-blinded, randomised | LPV/r + NVP (n = 26)                                                          | 533/133 mg BID + 200 mg BID           | Changes in body composition and metabolic abnormalities. After 24 months, limb fat in the ZDV/3TC/LPV/r group was 1223±318 g lower than in the NVP/LPV/r group (P = 0.0002). At 24 months, 17/22 (77%) of the patients in the ZDV/3TC/LPV/r group and 21/26 (80%) in the NVP/LPV/r group had plasma HIV-RNA < 50 copies/mL |
|                  | CTN 177    | 96 weeks     | Multicentre, randomised, prospective, open label | LPV/r + NVP (n = 26)                                                          | 533/133 mg BID + 200 mg BID           | Evaluate 48-week changes in mtDNA: nDNA ratio and efficacy, % (n) VL <50, ITT 48 weeks, safety, changes in metabolic parameters. LPV/r + NVP: −0.06, 42%; NVP + ZDV/3TC: −0.08, 50%; LPV/r + ZDV/3TC +0.26, 68% |

3TC, lamivudine; ARV, antiretroviral; ATV, atazanavir; ATV/r, atazanavir/ritonavir; BID, twice a day; DRV/r, darunavir/ritonavir; EFV, efavirenz; IDMC = independent data monitoring company; ITT, intent-to-treat; LPV/r, lopinavir/ritonavir; MVC, maraviroc; NRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine, PI/r, ritonavir-boosted protease inhibitor; PP, per protocol; QD, once a day; r, ritonavir; RAL, raltegravir; TDF/FTC, tenofovir/emtricitabine; VF, virologic failure; ZDV, zidovudine.

doi:10.1371/journal.pone.0148231.t001
| Regimen | Study Name | Treatment Arm | HIV-1 RNA <50 Copies/mL at Week 48 (Unless Specified) | Mean/ Median CD4 Increase (cells/mm³) at Week 48 (Unless Specified) | Discontinuations, n (%) | Treatment Failures/ Virologic Failures, n (%) | Mutations |
|---------|------------|---------------|-------------------------------------------------------|----------------------------------------------------------------|------------------------|---------------------------------------------|-----------|
| PI/r + RAL | SPARTAN [16] | ATV + RAL (n = 63, 45 evaluable at week 48) | 24 weeks: 74.6% (ITT); 48 weeks: 82.2% (OB: 37/45) | 24 weeks: 166; 48 weeks: 235 | 6 (9.5%) | 24 weeks VF: 11/63 (17.5%) | 4 patients: Q148R (1), Q148Q/R and T97T/A (1), and N155H (2). No PI mutations |
| | | ATV/r + TDF/ FTC (n = 30, 25 evaluable at week 48) | 24 weeks: 63.3% (ITT); 48 weeks: 76.0% (OB: 19/25) | 24 weeks: 127; 48 weeks: 197 | 3 (10%) | 24 weeks VF: 8/30 (26.7%) | None reported |
| | RADAR [17,18] | DRV/r + RAL (n = 40) | HIV-1 RNA <48 copies/mL; 24 weeks: 88.9%; 48 weeks: 62.5% | 24 weeks: 123 | 3 (9%) | 24 weeks VF: 2/39 (5.1%) | PI mutation: A71T (1); RAL testing pending |
| | | DRV/r + TDF/ FTC (n = 40) | HIV-1 RNA <48 copies/mL; 24 weeks: 81.0%; 48 weeks: 83.7% | 24 weeks: 174 | 3 (9%) | 24 weeks VF: 0/40 (0%) | None reported |
| | ACTG A5262 [19] | DRV/r + RAL (N = 112) | HIV-1 RNA <48 copies/mL; 24 weeks: 79% (ITT); 48 weeks: 71% (ITT) | 200 | 15 (13%) | 24 weeks VF: 17/not reported (16%); 48 weeks VF: 28/not reported (26%) | 5 of 25 tested: N155H (1), N155H/N (2), Q148G/R and N155H/N (1), Q148K/Q and N155H/N (1). No PI mutations in 23 tested |
| | NEAT 001/ ANRS143 [20] | DRV/r + RAL (n = 401) | HIV-1 RNA <48 copies/mL; 24 weeks: 85.4% (ITT); 48 weeks: 83.7% | 96 weeks: 267 | Not reported | VF: 17.4% | 5/28; NRTI, 1 (K65R); INI, 5 (N155H). No PI mutations. |
| | | DRV/r + TDF/ FTC (n = 404) | HIV-1 RNA <48 copies/mL; 24 weeks: 77.6% (ITT); 48 weeks: 83.7% | 96 weeks: 266 | Not reported | VF: 13.7% | 0/13. No mutations reported. |
| | CCTG 589 [21] | LPV/r + RAL (n = 26) | HIV-1 RNA <40 copies/mL; 48 weeks: 69% (ITT); 96 weeks: 69% (ITT) | 194 | 4 (15.4%) | No discontinuations due to VF | None reported |
| | | EFV/TDF/FTC (n = 25) | HIV-1 RNA <48 copies/mL; 48 weeks: 84% (ITT); 96 weeks: 84% (OB) | 116 | 2 (8%) | No discontinuations due to VF | None reported |
| | PROGRESS [22–25] | LPV/r + RAL (n = 101) | HIV-1 RNA <40 copies/mL; 48 weeks: 83.2% (ITT); 96 weeks: 66.3% (ITT); 88.9% (OB) | 48 weeks: 215; 96 weeks: 281 | 48 weeks: 8 (7.9%); 96 weeks: 19 (18.8%) | 96 weeks VF: 8/99 (8.1%) | 3/8; IN N155/H and G163/R (1); IN N155/H, G163/R (1); IN N155H, T97A, D232N, Pr. M46I, V32I, H71V (1); IN G140/S, Q148H/H1/S/RT M184V (1) |
| | | LPV/r + TDF/ FTC (n = 105) | HIV-1 RNA <40 copies/mL; 48 weeks: 84.8% (ITT); 96 weeks: 68.6% (ITT); 85.2% (OB) | 48 weeks: 245; 96 weeks: 296 | 48 weeks: 11 (10.5%); 96 weeks: 15 (14.3%) | 96 weeks VF: 5/104 (4.8%) | None detected |
| PI/r + MVC | A4001078 [26,28,30] | ATV/r + MVC (n = 60) | HIV-1 RNA <40 copies/mL; 48 weeks: 74.6% (ITT); 96 weeks: 67.8% (ITT) | 48 weeks: 215; 96 weeks: 269 | 48 weeks: 7 (11.7%); 96 weeks TF: 2/59 (3.4%); 96 weeks TF: 3/59 (5.1%) | None detected |
| | | ATV/r + TDF/ FTC (n = 61) | HIV-1 RNA <40 copies/mL; 48 weeks: 83.6% (ITT); 96 weeks: 82.0% (ITT) | 48 weeks: 226; 96 weeks: 305 | 48 weeks: 7 (11.5%); 96 weeks TF: 2/61 (3.3%); 96 weeks TF: 2/61 (3.3%) | None detected |

(Continued)
| Regimen | Study Name | Treatment Arm | HIV-1 RNA <50 Copies/mL at Week 48 (Unless Specified) | Mean/ Median CD4 Increase (cells/mm³) at Week 48 (Unless Specified) | Discontinuations, n (%) | Treatment Failures/ Virologic Failures², n (%) | Mutations |
|---------|------------|---------------|-----------------------------------------------------|------------------------------------------------------------------|------------------------|---------------------------------------------|-----------|
| MIDAS [31] | DRV/r + MVC (N = 24) | 24 weeks: 87.5%; 48 weeks: 83.3% | 247 | Not reported | 24 weeks VF: 3/24 (12.5%); 48 weeks VF: 4/24 (16.7%) | Not reported |
| MODERN [32] | DRV/r + TDF/FTC (n = 406) | 86.8% | 48 weeks: 194 | 48 weeks: 50/401 (12.5%) | 48 weeks TF: 13/401 (3.2%) | Not reported |
| | DRV/r + MVC (n = 406) | 77.3% | 48 weeks: 195 | 48 weeks: 73/396 (18.4%) | 48 weeks TF: 40/396 (10.1%) | Not reported |
| VEMAN [27,29] | LPV/r + MVC (n = 26) | 100% (PP: 26/26) | 286 | None reported | None (PP) | None reported |
| | LPV/r + TDF/FTC (n = 24) | 96% (PP: 22/24) | 199 | None reported | None reported (PP) | None reported |
| | LOREDA [33] | LPV/r + 3TC (N = 39) | HIV-1 RNA<48 copies/mL: 66.7% (ITT) | 250 | 12 (31%) | Discontinuations due to VF 44 weeks: 5/39 (12.8%) | No PI mutations; M184V in 3/3 tested |
| | GARDEL [34] | LPV/r + 3TC (n = 217) | 88.3% | 227 | 16 (4.5%) | 48 weeks VF: 10/214 (4.7%) | No primary PI mutations, M184V in 2/5 tested |
| | | LPV/r + 3TC or FTC + third NRTI (n = 209) | 83.7% | 217 | 27 (13.4%) | 48 weeks VF: 12/202 (5.9%) | 0/7 tested |
| BMS-121 [35] | ATV/r (300/100 mg) + EFV (n = 32) | 63% (ITT) | 271 | 5/32 (16%) | Not reported | Not reported |
| | ATV/r (400/100 mg) + EFV (n = 33) | 61% (ITT) | 250 | 7/33 (21%) | Not reported | Not reported |
| ACTG 5142 [36,37] | EFV + LPV/r (n = 250) | 96 weeks: 83% (PP) | 96 weeks: 273 | 164 patients (22%) | TF during median 112 weeks follow-up: 108/250 (43%); VF: 73/250 (29%) | 16%; NNRTI-associated: 37, K103N (31); PI-associated: 45, major (2); NRTI-associated: 6, M184V (1) |
| | LPV/r + 2 NRTIs (n = 253) | 96 weeks: 77% (PP) | 96 weeks: 287 | TF during median 112 weeks follow-up: 127/253 (50%); VF: 94/253 (37%) | 6%; PI-associated: 61, major (0); NRTI-associated: 15, M184V (13); NNRTI-associated: 2 | 9%; NNRTI-associated: 20, K103N (11); NRTI-associated: 14, M184V (8), K65R (3); PI-associated: 39, major (0) |
| | EFV + 2 NRTIs (n = 250) | 96 weeks: 89% (PP) | 96 weeks: 230 | TF during median 112 weeks follow-up: 95/250 (38%); VF: 60/250 (24%) | | |
| | MEDICLAS [38] | LPV/r + NVP (n = 26) | 24 months: 81% | 24 months: 308 | 7 | Not reported | Not reported |
| | LPVr + ZDV/3TC (n = 22) | 24 months: 77% | 24 months: 280 | 9 | Not reported | Not reported |
| CTN 177 [39] | LPV/r + NVP (n = 26) | 42% | 225 | AEs leading to discontinuation: 9/26 | Not reported | Not reported |
| NVP + ZDV/3TC (n = 26) | 50% | 134 | AEs leading to discontinuation: 2/26 | Not reported | Not reported | (Continued) |
ATV/r + TDF/FTC (19.7%) were of concern. Ten patients in this study switched from ATV/r to DRV/r or LPV/r due to toxicity issues [26,30]. Whether the ATV/r + MVC regimen is associated with improvement with other toxicity issues will require further examination of between-group differences in bone and immune activation markers [28]. In the MIDAS study (DRV/r + MVC; N = 24), the rate of VF was high, especially in patients with higher baseline viral loads; the virus was not suppressed at 48 weeks in 16.7% patients (4/24), despite reported perfect adherence to therapy [31].

A fourth study, A4001095 [32] (MODERN; N = 812), was designed to assess therapy with DRV/r + TDF/FTC and DRV/r + once-daily MVC, and utilized 150 mg MVC with DRV/r 800/100 mg once daily. This study was terminated early because of inferior efficacy in the MVC arm [32]. A switch to this combination in patients with virologic suppression remains under study in the MARCH trial, which has been fully recruited; however, results have not yet been reported.

3TC, lamivudine; AE, adverse event; ARV, antiretroviral; ATV, atazanavir; ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; EFV, efavirenz; ITT, intent-to-treat; LPV/r, lopinavir/ritonavir; MVC, maraviroc; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine, OB = observed; PI/r, ritonavir-boosted protease inhibitor; PP, per-protocol; r, ritonavir; RAL, raltegravir; TDF/FTC, tenofovir/emtricitabine; TF, treatment failure; VF, virologic failure; ZDV, zidovudine.

1Rows with italicized text indicate randomised and sufficiently powered dual therapy studies that showed comparable outcomes with the standard therapy.

2VF/TF as defined per individual study protocol; proportion calculated using modified ITT population (patients receiving at least 1 dose of study drug), where available.

doi:10.1371/journal.pone.0148231.t002

Table 2. (Continued)

| Regimen                  | Study Name  | Treatment Arm | HIV-1 RNA <50 Copies/mL at Week 48 (Unless Specified) | Mean/ Median CD4 Increase (cells/mm³) at Week 48 (Unless Specified) | Discontinuations, n (%) | Treatment Failures/ Virologic Failures², n (%) | Mutations                         |
|-------------------------|-------------|---------------|------------------------------------------------------|---------------------------------------------------------------------|-------------------------|-----------------------------------------------|-----------------------------------|
| LPV/r + ZDV/3TC (n = 25)|             | 68%           | 190                                                  | AEs leading to discontinuation: 02/25                               | Not reported            | Not reported                                  |                                   |

ATV/r + TDF/FTC (19.7%) were of concern. Ten patients in this study switched from ATV/r to DRV/r or LPV/r due to toxicity issues [26,30]. Whether the ATV/r + MVC regimen is associated with improvement with other toxicity issues will require further examination of between-group differences in bone and immune activation markers [28]. In the MIDAS study (DRV/r + MVC; N = 24), the rate of VF was high, especially in patients with higher baseline viral loads; the virus was not suppressed at 48 weeks in 16.7% patients (4/24), despite reported perfect adherence to therapy [31].

A fourth study, A4001095 [32] (MODERN; N = 812), was designed to assess therapy with DRV/r + TDF/FTC and DRV/r + once-daily MVC, and utilized 150 mg MVC with DRV/r 800/100 mg once daily. This study was terminated early because of inferior efficacy in the MVC arm [32]. A switch to this combination in patients with virologic suppression remains under study in the MARCH trial, which has been fully recruited; however, results have not yet been reported.

3TC, lamivudine; AE, adverse event; ARV, antiretroviral; ATV, atazanavir; ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; EFV, efavirenz; ITT, intent-to-treat; LPV/r, lopinavir/ritonavir; MVC, maraviroc; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine, OB = observed; PI/r, ritonavir-boosted protease inhibitor; PP, per-protocol; r, ritonavir; RAL, raltegravir; TDF/FTC, tenofovir/emtricitabine; TF, treatment failure; VF, virologic failure; ZDV, zidovudine.

1Rows with italicized text indicate randomised and sufficiently powered dual therapy studies that showed comparable outcomes with the standard therapy.

2VF/TF as defined per individual study protocol; proportion calculated using modified ITT population (patients receiving at least 1 dose of study drug), where available.

doi:10.1371/journal.pone.0148231.t002

PIs in Combination With Lamivudine

Two studies examined a PI/r in combination with lamivudine (3TC). In a single-arm pilot study (LOREDA, N = 39) [33], the LPV/r + 3TC combination demonstrated moderate virologic efficacy (66.7% of patients with viral load <48 copies/mL, ITT; 81.2%, as treated); however, VF was high (13%) [33]. The GARDEL study (N = 426) was a randomised, controlled, and powered study that compared LPV/r + 3TC with LPV/r + 2 NRTIs [34]. LPV/r + 3TC was noninferior to standard triple therapy at 48 weeks regardless of baseline viral loads (<50 copies/mL: dual therapy, 88.3%; triple therapy, 83.7%; P = 0.171). There were fewer discontinuations in the LPV/r + 3TC arm largely because of safety and toxicity reasons. VF occurred at low levels in both treatment arms and did not result in any PI resistance in either arm. The M184V mutation was identified in 2 of 5 patients in the LPV/r + 3TC arm. Because the second NRTI in the triple therapy arm was most commonly zidovudine (ZDV), the generalizability of these results to all NRTIs may be limited. However, when the comparison was limited to non–ZDV-containing regimens, noninferiority was confirmed.
Table 3. Results of key secondary endpoints from identified trials among ARV-naive patients.

| Regimen Arm | Study Name | Treatment Arm | Adverse Events | Lipids | Renal | Bone | Lipoatrophy | Other Notes |
|-------------|------------|---------------|----------------|--------|-------|------|-------------|-------------|
| PI/r + RAL  | SPARTAN    | ATV + RAL     | Grade 2–4 treatment-related AE hyperbilirubinemia, 17.5%; grade 4 hyperbilirubinemia, 20.6% | HDL↑ by 24%; Total cholesterol↑ by 7% at week 24 | Not reported | Not reported | Not reported | Based on the higher rates of hyperbilirubinemia and the development of resistance to RAL, the regimen was not considered optimal to support further clinical development and therefore the trial was terminated early. |
|             |            | (n = 63, 45 evaluable at week 48) | | | | | | |
|             |            | ATV + RAL     | Grade 2–4 treatment-related AE hyperbilirubinemia, 10.0%; Grade 4 hyperbilirubinemia, 0% | TG↑ by 32%; total cholesterol↑ by 10% at week 24 | Not reported | Not reported | Not reported | Patients in the TDF-containing arm had significantly more bone loss; markers of bone formation and destruction indicate a higher bone turnover. |
|             |            | (n = 30, 25 evaluable at week 48) | | | | | | |
| DRV/r + RAL | RADAR      | DRV/r + RAL   | 3 severe AEs; none related to treatment | There were no statistically significant differences between groups in changes from baseline for total cholesterol, TG, total cholesterol/HDL ratio or serum creatinine at week 24 | Not reported | Not reported | Not reported | |
|             |            | (n = 40) | | | | | | |
| DRV/r + TDF/FTC | ACTG A5262 | DRV/r + RAL   | Grade 3 or higher clinical or laboratory AEs were reported at least once by 19% of patients | Statistically significant median increases in: HDL: 9 mg/dL; LDL: 17 mg/dL; total cholesterol: 30 mg/dL; TG: 23 mg/dL | Not reported | Not reported | Not reported | Death occurred in one patient from cryptosporidiosis. |
|             |            | (N = 112) | | | | | | |
| DRV/r + TDF/FTC | NEAT001/ANRS143 | DRV/r + RAL   | Incidence rates of AEs (/100-PY) were similar between arms (TDF/FTC vs RAL): SAE, 8.3 vs 10.2; grade 3 or 4, 7.4 vs 9.6; Statistically significant increases in RAL vs TDF/FTC arms at 96 weeks (mmol/L): TC: 0.9 vs 2.0, LDL: 0.5 vs 0.4 | HDL– 0.2 vs 0.1 TC:HDL ratio did not change in either arm | eGFR (mL/min) changes at 96 weeks, RAL: +0.9; TDF/FTC: -3.8 (P = 0.02); mean changes in CrCl from BL to Wk 96 were +1.3 and -4.1 mL/min (P = 0.0004) | Not reported | Not reported | At 96 weeks, % of pts with grade 3/4 CK elevations, RAL: -6.2; TDF/FTC: 5.0 (P value not reported); AST/ALT elevations, RAL: 3.0; TDF/FTC: 1.0 (P value not reported). |
|             |            | (n = 401) | | | | | | |
| DRV/r + TDF/FTC |            | (n = 404) | | | | | | |

(Continued)
| Regimen   | Study Name | Treatment Arm | Adverse Events | Lipids | Renal | Bone | Lipoatrophy | Other Notes |
|-----------|------------|---------------|----------------|--------|-------|------|-------------|-------------|
| CCTG 589  | [21]       | LPV/r + RAL   | No serious AEs; no difference in time to grade 2–4 AEs | Median cholesterol and TG at week 48 were non-significantly higher with LPV/r + RAL than EFV/TDF/FTC | Not reported | Not reported | Not reported |
|           |            | (n = 26)      |                |        |       |      |             |             |
|           |            | EFV/TDF/FTC   | 2 serious AEs (including 1 possibly related suicide ideation) |        |       |      |             |             |
|           |            | (n = 25)      |                |        |       |      |             |             |
| PROGRESS  | [22–25]    | LPV/r + RAL   | AE profile and laboratory abnormalities were generally similar | No statistically significant differences between arms in mean change of lipid levels or lipid ratios (LDL: HDL and TC: HDL) | 96 weeks: eGFR, −1.43 mL/min | DEXA 96 weeks (n = 78) | Mean % change from BL for spine BMD: -1.34% and total BMD: 0.68% | Both regimens restored peripheral body fat; LPV/r + RAL increases in upper and lower extremity fat were statistically significantly higher vs LPV/r +TDF/FTC |
|           |            | (n = 101)     |                |        |       |      |             |             |
|           |            | LPV/r + TDF/FTC | 96 weeks: eGFR, −7.33 mL/min | DEXA 96 weeks (n = 82) | Mean % change from BL for spine BMD: -4.61%; total BMD: -2.48%; significant difference between arms |
|           |            | (n = 105)     |                |        |       |      |             |             |
| PI/r + MVC | A4001078  | ATV/r + MVC   | Grade 3 or 4 AE, 48.3% (36.7% hyperbilirubinemia) | Not reported | 48 weeks: CrCl stable; 96 weeks: CrCl: −5.5 mL/min | Formation markers were significantly different between arms | Not reported | 10 patients switched from ATV/r to another PI (7 DRV/r; 3 LPV/r) for tolerability or unconjugated hyperbilirubinemia |
|           | [26,28,30] | (n = 60)      |                |        |       |      |             |             |
|           |            | ATV/r + TDF/FTC | Grade 3 or 4 AE, 29.5% (19.7% hyperbilirubinemia) | Not reported | 48 weeks: CrCl decreased; 96 weeks: CrCl: −18 mL/min | Not reported | Not reported | Not reported |
|           |            | (n = 61)      |                |        |       |      |             |             |
| MIDAS     | [31]       | DRV/r + MVC   | Not reported | LDL cholesterol increased to grade 3 in one patient | Not reported | Not reported | Not reported |
|           |            | (N = 24)      |                |        |       |      |             |             |
| MODERN    | [32]       | DRV/r + TDF/FTC | Grade 3 or 4 AEs similar between groups | Not reported | Not reported | Not reported | Not reported | (Continued) |
| Regimen | Study Name | Treatment Arm | Adverse Events | Lipids | Renal | Bone | Lipoatrophy | Other Notes |
|---------|------------|---------------|----------------|--------|-------|------|-------------|-------------|
| DRV/r + MVC (n = 406) | No grade 3 or grade 4 AEs | Cholesterol (total, HDL, LDL, and TG) stable; no significant difference between arms | Not reported | Not reported | Not reported | Not reported | Not reported |
| VEMAN [27,29] | LPV/r + MVC (n = 28, 19 evaluable) | No grade 3 or grade 4 AEs | Not reported | Not reported | Not reported | Not reported | Glucose and insulin stable; no significant difference between arms |
| LOREDA [33] | LPV/r + TDF/FTC (n = 27, 19 evaluable) | Diarrhoea led to 3 treatment interruptions | Not reported | Not reported | Not reported | Not reported | Not reported |
| GARDEL [34] | LPV/r + TDF/FTC (n = 27, 19 evaluable) | 65 grade 2 or 3 AEs, 43 patients with grade 2–3 AEs | 11% with grade 2–3 AEs | Not reported | Not reported | Not reported | Not reported |
| BMS-121 [35] | ATV/r (300/100) + EFV (n = 32) | Grade 2–4 AEs = 26% | Mean change from BL (%) in total cholesterol, LDL, HDL, and TG = 29, 11, 54, and 48, respectively. | Increase in grade 3–4 total bilirubin, ALT, and AST by 13%, 10%, and 7%. | Not reported | Not reported | Not reported |
| | ATV/r (400/100) + EFV (n = 33) | Grade 2–4 AEs = 30% | Mean change from BL (%) in total cholesterol, LDL, HDL, and TG = 32, 13, 45, and 63, respectively. | Increase in grade 3–4 total bilirubin, ALT, and AST by 40%, 7%, and 3% | Not reported | Not reported | Not reported |
| ACTG 5142 [36,37] | EFV + LPV/r (n = 250) | Grade 3 or 4 new clinical event = 43 (17%); Grade 3 or 4 laboratory abnormality = 107 (43%) | LDL >190 mg/dL = 14 (6%); TG >750 mg/dL = 34 (14%) | Creatinine kinase >5 times ULN = 14 (6%) | Clinical lipoatrophy = 0; mean limb fat increases: 1.1 kg |
| | LPV/r + 2 NRTIs (n = 253) | Grade 3 or 4 new clinical event = 46 (18%); Grade 3 or 4 laboratory abnormality = 80 (32%) | LDL >190 mg/dL = 2 (1%); TG >750 mg/dL = 16 (6%) | Creatinine kinase >5 times ULN = 8 (3%) | Not reported | Clinical lipoatrophy = 3 (1%); mean limb fat increases: 0.7 kg |

(Continued)
| Regimen | Study Name | Treatment Arm | Adverse Events | Lipids | Renal | Bone | Lipoatrophy | Other Notes |
|---------|------------|---------------|----------------|--------|-------|------|-------------|------------|
| EFV + 2 NRTIs (n = 250) | Grade 3 or 4 new clinical event = 42 (17%); Grade 3 or 4 laboratory abnormality = 72 (29%) | LDL >190 mg/dL = 7 (3%); TG >750 mg/dL = 6 (2%) | Creatine kinase >5 times ULN = 8 (3%) | Not reported | Clinical lipoatrophy = 8 (3%) mean limb fat increases: 0.05 kg |
| MEDICLAS [38] | LPV/r + NVP (n = 26) | Grade 3 or 4 AEs, 54.2% | Total cholesterol and HDL increased by 36.5% and 38/8% | Not reported | Not reported | At 24 months, total fat increased to 15643 g. |
| LPV/r + ZDV/3TC (n = 22) | Grade 3 or 4 AEs, 45.8% | Total cholesterol and HDL increased by 23.2% and 32.8% | Not reported | Not reported | At 24 months, total fat increased to 14254 g |
| CTN 177 [39] | LPV/r + NVP (n = 26) | Grade 3 or 4 AEs, 34.6% | Median changes from BL to week 48 in TC, HDL, and TG of +1.8, +0.6, and +0.4 mmol/L, respectively | Not reported | Not reported | Not reported |
| NVP + ZDV/3TC (n = 25) | Grade 3 or 4 AEs, 7.4% | Median changes from BL to week 48 in TC, HDL, and TG of +0.8, +0.4, and −0.1 mmol/L, respectively | Not reported | Not reported | Not reported |
| LPV/r + ZDV/3TC (n = 25) | Grade 3 or 4 AEs, 8.33% | Median changes from BL to week 48 in TC, HDL, and TG of +1.3, +0.2, and +0.9 mmol/L, respectively | Not reported | Not reported | Not reported |

3TC, lamivudine; AE, adverse event; ALT, alanine aminotransferase; ARV, antiretroviral; AST, aspartate aminotransferase; ATV, atazanavir; ATV/r, atazanavir/ritonavir; BL, baseline; BMD, bone mineral density; DRV/r, darunavir/ritonavir; eGFR, estimated glomerular filtration rate; EFV, efavirenz; HDL, high-density lipoprotein; ITT, intent-to-treat; LDL, low-density lipoprotein; LPV/r, lopinavir/ritonavir; MVC, maraviroc; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine, PI/r, ritonavir-boosted protease inhibitor; PP, per-protocol; PY, person-years; r, ritonavir; RAL, raltegravir; SAE, serious adverse event; TDF/FTC, tenofovir/emtricitabine; TG, triglycerides; ZDV, zidovudine.

doi:10.1371/journal.pone.0148231.t003
PIs in Combination With NNRTIs

Four studies evaluating a PI/r (LPV/r or ATV/r) in combination with an NNRTI (EFV) were identified. In BMS-121 [35] (N = 65), which compared ATV/r (300/100 mg) + EFV with ATV/r (400/100 mg) + EFV, rates of virologic suppression were similar with either treatment combination. In ACTG 5142 [36,37] (N = 753), time to VF was similar in the LPV/r + EFV arm when compared with the triple therapy arms; however, resistance (any mutation [excluding minor protease mutations] and NNRTI-associated mutations) and grades 3 and 4 laboratory events were more common with LPV/r + EFV. In the MEDICLAS study [38] (N = 48), patients receiving LPV/r + nevirapine (NVP) or LPV/r + ZDV/3TC had similar rates of virologic suppression (80% and 77%, respectively). In the CTN 177 study [39] (N = 77), rates of virologic suppression were lower with LPV/r + NVP versus NVP + ZDV/3TC or LPV/r + ZDV/3TC. Discontinuations related to AEs (rash and elevated transaminases) were more frequent in the LPV/r + NVP arm compared with the other treatment arms [39].

Trials of ARV-Experienced, Virologically Suppressed Patients

Another approach to an ARV-sparing strategy is to suppress patient HIV-RNA levels using standard triple ARV regimens and then switch or simplify to a dual therapy regimen. Thirteen trials were identified that examined novel dual therapy regimens in ARV-experienced, virologically suppressed patients. Trial designs and key findings from these studies are summarised in Tables 4, 5 and 6. Virologic efficacy endpoints are summarised in Fig 2B.

PIs in Combination With RAL

Five small studies assessed treatment simplification to PI/r + RAL-based regimens in virologically suppressed patients. In the BATAR study [40] (ATV/r + RAL, n = 15; ATV + RAL, n = 14; ATV/r + TDF/FTC, n = 14), 95% of patients (41/43) overall maintained viral suppression (≤200 copies/mL) at 48 weeks; 2 VF occurred with ATV + RAL. In the Ruane study [41] (ATV + RAL [N = 30]), 23 patients who remained on protocol after a median of 72 weeks of therapy maintained virologic suppression (<48 copies/mL). In the ongoing SPARE study [42] (N = 59), which is evaluating DRV/r + RAL compared with LPV/r + TDF/FTC, all patients maintained virologic suppression (<50 copies/mL) at week 48. In the Calza 2013 study [43] (DRV/r + RAL; N = 71), 94% (67/71) of patients maintained viral suppression (<50 copies/mL) at 12 months. The KITE study [44] (N = 60), which assessed simplification to LPV/r + RAL from standard highly active antiretroviral therapy (HAART), demonstrated efficacy (virologic suppression <50 copies/mL) and safety comparable with continuing HAART over 48 weeks.

PIs in Combination With 3TC

Two studies of a PI/r in combination with 3TC were identified. In the single-arm ATLAS trial [45–47] (N = 40), simplification to therapy with ATV/r + 3TC demonstrated maintenance of virologic efficacy (<50 copies/mL) and no grade 4 laboratory toxicities or treatment interruptions due to the development of new laboratory toxicities at 96 weeks. In the SALT study [48] (N = 131), 87.5% of virologically suppressed patients who received ATV/r + 3TC maintained virologic suppression (<50 copies/mL) compared with 92.5% of patients who received ATV/r + 2 NRTIs (95% CI, −26.3% to 15.5%) at 24 weeks. The OLE study is an open-label prospective study evaluating LPV/r + 3TC or FTC compared with LPV/r + 2 NRTIs, which is ongoing through 48 weeks; results have not yet been reported [49].
Fig 2. Efficacy of therapy by regimen in A) in ARV-naive, and B) ARV-experienced, virologically suppressed patients. Percentage indicated shows subjects with HIV-1 RNA <50 copies/mL at week 48. Studies that were randomised and sufficiently powered for direct comparison of standard and dual therapy regimens are shaded. ARV, antiretroviral.

doi:10.1371/journal.pone.0148231.g002
Table 4. Study designs for identified trials in ARV-experienced, virologically suppressed patients.

| Regimen | Study Name | Duration | Type | Suppression Criteria | Treatment Arm | Dose | Primary Endpoint |
|---------|------------|----------|------|--------------------|---------------|------|------------------|
| PI/r + RAL | BATAR [40] | 48 weeks | Open-label, exploratory, pilot trial | HIV viral load <50 copies/mL | ATV/r + RAL (arm 1; n = 15) | 300/100 mg QD + 400 mg BID | Maintenance of virologic suppression (<40 c/mL); all but two patients maintained virologic suppression; both virologic failures (>200 c/mL on two consecutive tests) were on arm 2 (ATV + RAL, both BID) |
|         |            |          |      |                    | ATV + RAL (arm 2; n = 14) | 300 mg BID + 400 mg BID |    |
|         |            |          |      |                    | ATV/r + TDF/FTC (ctrl; n = 14) | 300/100 mg QD + 300/200 mg QD |    |
| PI/r + 3TC | Ruane [41] | 48 weeks, switch to 96 weeks | Prospective, single-centre, single-arm switch study, with extension | HIV viral load <48 copies/mL | ATV + RAL (N = 30) | 400 mg QD + 400 mg BID | VL <48 copies/mL by week 48 |
|         |            |          |      |                    | LPV/r + TDF/FTC (n = 30) | 800/200 mg per day + 300/200 mg QD | Virologic efficacy and safety |
| PI/r + 2 NRTIs | Calza 2013 [43] | 12 months | Prospective, observational | HIV viral load <50 copies/mL | DRV + RAL (n = 71) | 800/100 mg QD + 400 mg BID | HIV-1 RNA <50 copies/mL at week 48 (ITT): 91.7% vs 88.2% |
|         |            |          |      |                    | HAART (n = 20) | NA |    |
| PI/r + NNRTI | ATLAS [46,47] | 48 weeks extended to 96 weeks | Single-arm, prospective, pilot study | <50 copies/mL for >3 months previously on HIV/AIDS-based regimen (39 TDF; 1 abacavir) | ATV + 3TC (n = 40) | ATV/r (300 mg/100 mg QD) + 3TC (300 mg QD) | Time to confirmed VF (2 consecutive HIV-1 RNA >200 copies/mL) |
|         |            |          |      |                    | ATV/r + 3 TC (n = 64) | 300/100 mg QD + 300 mg QD | Stopping rule set at 5 VF defined as HIV-RNA>50 c/mL |
|         |            |          |      |                    | ATV/r + 2 NRTIs (n = 67) | NA |    |
| PI/r + NNRTI | SALT [48] | 96 weeks | Randomised, open-label | HIV viral load <50 copies/mL | LPV/r + 3TC (n = 64) | 400/100 mg QD + 400 mg BID | VL <50 c/mL: 87.5% (dual) vs 92.5% (triple) (difference -5%; 99.95% CI, -26.3% to 15.5%) |
|         |            |          |      |                    |               | NA |    |
|         |            |          |      |                    |               | NA |    |
| PI/r + NNRTI | A5116 [50] | 72 weeks | Multicenter, randomised, open-label study | <200 copies/mL for >18 months previously on stable 3 or 4 PI- or NNRTI-based regimen | EFV + LPV/r (n = 118) | 600 mg QD + 533/133 mg BID | Time to confirmed VF (2 consecutive HIV-1 RNA >200 copies/mL) |
|         |            |          |      |                    | EFV + 2 NRTIs (n = 118) | 600 mg QD + as appropriate |    |
|         |            |          |      |                    |               | NA |    |
| PI/r + NNRTI | NEKA [51] | 48 weeks | Randomised, open-label pilot study | <80 copies/mL previously on the same PI- or NNRTI-based regimen for >9 months | LPV/r + NVP (n = 16) | 400/100 mg BID + 2 NRTIs | HIV-1 RNA <80 copies/mL at week 48 (ITT): 87.5% vs 100% |

(Continued)
PIs in Combination With NNRTIs

In A5116 [50] (N = 236), the combination of LPV/r + EFV was associated with increased toxicity-related discontinuations and a trend towards increased rates of VF (2 consecutive plasma HIV-1 RNA >200 copies/mL) compared with EFV + 2 NRTIs. In the NEKA study [51] (N = 31), in which virologically suppressed patients were switched to LPV/r + NVP or continued with LPV/r + 2 NRTIs, the proportion of patients who maintained virologic suppression were comparable, and LPV/r + NVP was generally well-tolerated over 48 weeks. Data regarding simplification of a 2-ARV regimen combining PI/r with rilpivirine, which could decrease pill burden and lessen toxicity, are not currently available.

Integrase Inhibitors in Combination With NNRTIs

Reliquet 2014 [52] (N = 39) evaluated simplification of therapy to raltegravir (RAL) in combination with NVP. At 12 months following a switch of therapies from NVP + a non-RAL ARV, 82.1% of patients (ITT analysis) maintained virologic suppression (<50 copies/mL for more than 6 months on an NVP-containing regimen) RAL + NVP (N = 39) 400 mg BID + 400 mg QD Not reported

Calin 2013 [53] was a study (N = 91) that evaluated simplification to RAL in combination with etravirine (ETR). At week 48, the discontinuation rate was 20%, including 3 patients who discontinued because of VF (2 consecutive plasma viral load >50 copies/mL).

Integrase Inhibitors in Combination With MVC

Two studies examined simplification to RAL in combination with MVC from a suppressive ARV [54] or RAL + MVC + TDF/FTC [55]. The ROCnRAL ANRS 157 study [54] (N = 44) was discontinued because of a high rate (n = 5) of VF (2 consecutive plasma viral load >50 copies/mL) after a median duration of 20 weeks. In the No Nuc No Boost study [55] (N = 10),

3TC, lamivudine; ARV, antiretroviral; ATV/r, atazanavir/ritonavir; BID, twice a day; DRV/r, darunavir/ritonavir; EFV, efavirenz; eGFR, estimated glomerular filtration rate; ETR = etravirine; HAART, highly active antiretroviral therapy; ITT, intent-to-treat; LPV/r, lopinavir/ritonavir; MVC, maraviroc; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI/r, ritonavir-boosted protease inhibitor; PP, per-protocol; QD, once a day; RAL, raltegravir; TDF, tenofovir; TDF/FTC, tenofovir/emtricitabine; TF, treatment failure; VF, virologic failure; VL, viral load.

doi:10.1371/journal.pone.0148231.t004
Table 5. Results of key efficacy endpoints from identified trials in ARV-experienced virologically suppressed patients.

| Regimen       | Study Name | Treatment Arm | HIV-1 RNA <50 Copies/mL at Week 48 (Unless Specified) | Mean/Median CD4 Increase (cells/mm³) at Week 48 (Unless Specified) | Discontinuations, n | Treatment Failures/ Virologic Failures¹, n (%) | Mutations                                                                 |
|---------------|------------|---------------|------------------------------------------------------|-------------------------------------------------------------------|---------------------|---------------------------------------------|--------------------------------------------------------------------------|
| PI/r + RAL    | BATAR [40] | ATV/r + RAL   | 48 weeks: 100% (15/15)                               | Overall CD4 counts were 534/mm³ at BL and 555/mm³ at week 48. There was a significant CD4 cell count difference favouring ATV/r- TDF/FTC (52/mm³) vs arm 2 (14/mm³); P = 0.03 | Not reported        | 48 weeks VF: 0/15 (0%)                      | Mutations                                                                 |
|               |            | (n = 15)      |                                                      |                                                                   |                     |                                             |                                                                          |
|               |            | ATV + RAL     | 48 weeks: 85.7% (12/14)                              |                                                                   | 48 weeks VF: 2/14 (14.3%) | None detected                              |                                                                          |
|               |            | (n = 14)      |                                                      |                                                                   |                     |                                             |                                                                          |
|               |            | ATVR + TDF/FTC| 48 weeks: 100% (14/14)                               |                                                                   | 48 weeks VF: 0/14 (0%) | Not reported                              |                                                                          |
|               |            | (n = 14)      |                                                      |                                                                   |                     |                                             |                                                                          |
|               | Ruane [41] | ATV + RAL     | 23/30 patients remain on protocol (median, 72 weeks; range, 36–96) and all have HIV VL <48 copies/mL | The median (range) increase (LOCF) in the absolute CD4 count from BL to week 48 was 64 (53–100) cells/mm³ | 2                   | VF: 4/30 (13.3%)                            |                                                                          |
|               |            | (N = 30)      |                                                      |                                                                   |                     |                                             |                                                                          |
|               | SPARE (ongoing) [42] | DRV/r + RAL  | 24 weeks: 96.2% (PP), 89.3% (ITT); 48 weeks: 100% (PP), 85.7% (ITT) | Not reported | 4                   | None reported                              |                                                                          |
|               |            | (n = 29)      |                                                      |                                                                   |                     |                                             |                                                                          |
|               |            | LPV/r + TDF/FTC| 24 weeks: 96.7% (PP and ITT); 48 weeks: 100% (PP), 96.7% (ITT) | Not reported | 1                   | None reported                              |                                                                          |
|               | Calza 2013 | DRV/r + RAL   | 12 months: 94% (ITT)                                 |                                                                   | 12 months VF: 1/71 (1.4%) | None reported                              |                                                                          |
|               |            | (N = 71)      |                                                      |                                                                   |                     |                                             |                                                                          |
|               | KITE [44]  | LPV/r + RAL   | 91.7% (ITT)                                          |                                                                   | 48 weeks TF: 4/39 (10.3%); 1/39 (2.6%) due to VF                 | None reported                              |                                                                          |
|               |            | (n = 40)      |                                                      |                                                                   |                     |                                             |                                                                          |
|               |            | HAART         | 88.2% (ITT)                                          |                                                                   | 48 weeks TF: 2/20 (10.0%); both due to VF                       | None reported                              |                                                                          |
|               |            | (n = 20)      |                                                      |                                                                   |                     |                                             |                                                                          |
| PI/r + 3TC    | ATLAS [45–47] | ATV/r + 3TC  | Week 48: 90% (ITT); Week 96: 85% (ITT)               |                                                                   | 33                  | Not reported                               | 0/2                                                                      |
|               |            | (N = 40)      |                                                      |                                                                   |                     |                                             |                                                                          |
|               | SALT [48]  | ATV/r + 3TC   | Week 24: 87.5%                                       |                                                                   | 57                  | Week 24 VF: 0/64 (0%)                       | NA                                                                       |
|               |            | (n = 64)      |                                                      |                                                                   |                     |                                             |                                                                          |
|               |            | ATV/r + 2 NRTIs| Week 24: 92.5%                                       |                                                                   | −27                 | Week 24 VF: 0/67 (0%)                      | NA                                                                       |
|               |            | (n = 67)      |                                                      |                                                                   |                     |                                             |                                                                          |
| PI/r + NNRTI  | A5116 [50] | EFV + LPV/r   | Not reported                                         |                                                                   | 48 weeks: 40.4; 96 weeks: 67.8 | 20              | TF during median 110 weeks follow-up: 34/115 (29.6%); VF: 14/115 (12.2%) | In reverse transcriptase, M184V (1), K103N (5), V106A/M (2), Y188H (1), G190A (2), V108I (1) In protease, L33V (2) and F53L (1). |
|               |            | (n = 118)     |                                                      |                                                                   |                     |                                             |                                                                          |

(Continued)
HIV-RNA levels remained <50 copies/mL in 9 of 10 patients following 44 weeks of treatment with RAL + MVC.

Secondary Endpoint Findings From Trials of ARV-Naive and ARV-Experienced, Virologically Suppressed Patients

The main rationale for dual therapy is to optimize health status and quality of life without compromising control of HIV infection. Toxicities and comorbidities may interfere with patient quality of life and negatively affect adherence to ARV regimens and can lead to additional costs for diagnosis and management. Thus, an ideal regimen would provide potent virologic suppression while conferring a lower risk of long-term, ARV-related AEs and would minimally affect any comorbidities that may be present.

Table 5. (Continued)

| Regimen | Study Name | Treatment Arm | HIV-1 RNA <50 Copies/mL at Week 48 (Unless Specified) | Mean/Median CD4 Increase (cells/mm³) at Week 48 (Unless Specified) | Discontinuations, n | Treatment Failures/ Virologic Failures¹, n (%) | Mutations |
|---------|------------|---------------|------------------------------------------------------|-----------------------------------------------------------------|----------------------|-----------------------------------------------|-----------|
| EFV + 2 NRTIs (n = 118) | - | Not reported | 48 weeks: 17.4; 96 weeks: 43.6 | 14 | TF during median 110 weeks follow-up: 13/117 (11.1%); VF: 7/117 (6.0%) | In reverse transcriptase, M184V/i (5), K103N (5), V106M (1), M230L (1), P225H (1). In protease, L33V (1) |
| NEKA [51] | LPV/r + NVP (n = 16) | HIV-1 RNA <80 copies/mL: 87.5% (NVP group) and 100% NRTI group | 300 | 2 | Not reported | Not reported |
| NEKA [51] | LPV/r + 2 NRTIs (n = 15) | - | 155 | 0 | - | - |
| RAL + NNRTI | Reliquet 2014 [52] | RAL + NVP (N = 39) | 6 months: 87.2% (ITT); 97.1% (PP); 12 months: 82.1% (ITT); 94.1% (PP) | Not reported | 6 | VF during median 27 months follow-up: 1/39 (2.6%) | In 1 patient at VF, G190A, G140G/S, Q148H |
| Calin 2013 [53] | RAL + ETR (N = 91) | 6 months: 98.2% (PP); 12 months: 92.3% (PP) | Not reported | 18 | VF during median 11.5 months follow-up: 5/91 (5.5%) | In 3/5 cases, VF was followed by acquired RAL (N155H, Q148H) and ETR (Y181V) mutations |
| RAL + MVC | ROCnRAL ANRS157 [54] | RAL + MVC (N = 44) | For virologic reasons, study was discontinued early. At end, all but 3 were ART-controlled | No change | 4 | 24 weeks TF: 7/44 (15.9%); VF: 5/44 (11.4%) | Resistance mutations emerged in 3/5 VF patients: Y143C, N155H, F121Y |
| No Nuc Boost [55] | RAL + MVC (N = 10) | - | Approximately 750 | 0 | 48 weeks VF: 0/10 (0.0%) | Not reported |

3TC, lamivudine; ART, antiretroviral therapy; ARV, antiretroviral; ATV/r, atazanavir/ritonavir; BL, baseline; DRV/r, darunavir/ritonavir; EFV, efavirenz; ETR = etravirine; HAART, highly active antiretroviral therapy; ITT, intent-to-treat; LOCF, last observation carried forward; LPV/r, lopinavir/ritonavir; MVC, maraviroc; NA, not available; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI/r, ritonavir-boosted protease inhibitor; PP, per protocol; r, ritonavir; RAL, raltegravir; TDF, tenofovir; TDF/FTC, tenofovir/emtricitabine; TF, treatment failure; VF, virologic failure; VL, viral load.

¹VF/TF as defined per individual study protocol; proportion calculated using modified ITT population (patients receiving at least 1 dose of study drug) when available.

doi:10.1371/journal.pone.0148231.t005
Table 6. Results of key secondary endpoints from identified trials among ARV-experienced HIV-suppressed patients.

| Regimen | Study Name | Treatment Arm | Adverse Events | Lipids | Renal | Bone | Lipoatrophy |
|---------|------------|---------------|----------------|--------|-------|------|-------------|
| PI/r + RAL | BATAR [40] | ATV/r + RAL (arm 1; n = 15) | Neurologic; n = 7; musculoskeletal, n = 3 | No significant difference between groups | Not reported | Not reported | Not reported |
| | | ATV/r + RAL (arm 2; n = 14) | Neurologic; n = 6; musculoskeletal, n = 7 | | | | |
| | | ATV/r + TDF/FTC (control, n = 14) | Neurologic; n = 1; musculoskeletal, n = 1 | | | | |
| Ruane [41] | ATV + RAL (N = 30) | AEs were generally mild to moderate in severity. No grade 4 AEs were reported. Two grade 3 AEs were reported, nausea and weight loss, both of which were considered not related to study drug | | Decreases in TC, TG, LDL, and HDL were observed | Not reported | Not reported | Not reported |
| SPARE (ongoing) [42] | DRV/r + RAL (n = 29) | Grade 3 or 4 AEs at least one grade higher than baseline: rise in ALT (due to acute hepatitis B infection, n = 1) and elevated LDL cholesterol (n = 3) | | | | |
| | | | | | | | |
| | LPV/r + TDF/FTC (n = 30) | Grade 3 or 4 AEs at least one grade higher than baseline: elevated LDL cholesterol (n = 1), and hypophosphatemia (n = 3) | | | | |
| Calza 2013 [43] | DRV/r + RAL (N = 71) | Gastrointestinal symptoms, n = 3; virologic failure (n = 1) | Mean TG −57 mg/dL (P<0.05) compared with baseline | | | |
| | | | | | | |
| KITE [44] | LPV/r + RAL (n = 40) | No serious AEs during the study; other than myalgia (25% in HAART vs 0), no differences between groups in AEs; trend towards more diarrhoea in LPV/r + RAL | Adjusted mean HDL levels and LDL levels were not statistically significantly different between groups. Total cholesterol and TG significantly lower in HAART arm at week 24 | | | |
| | | | | | | |
| | HAART (n = 20) | | | | | | |

(Continued)
### Table 6. (Continued)

| Regimen       | Study Name | Treatment Arm | Adverse Events                                      | Lipids                                                                 | Renal                                                                 | Bone                                                                 | Lipoatrophy                                                                 |
|---------------|------------|---------------|----------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------|
| PI/r + 3TC    | ATLAS [45–47] | ATV/r + 3TC (N = 40) | 6 severe AEs at 48 weeks: 4 renal colic, 1 hypertensive crisis, 1 brain haemorrhage | Significant changes at 48 weeks: TC, +15 mg/dL; HDL, +6 mg/dL; 96 weeks: TC, +19 mg/dL; HDL, +5 mg/dL | Significant changes at 48 weeks: eGFR CG: 6 mL/min; 96 weeks: MDRD: 15 mL/min | 48 weeks: trend towards increase in L2–L4 BMD: 0.01 g/cm²; osteoporosis in 7% BL and 8% at 48 weeks; osteopenia in 40% and 38%, respectively; significant decreases in osteocalcin (−12 mg/mL) and alkaline phosphatase (−40 UI/L); no significant changes were observed in serum calcium, PTH, or vitamin D | At 48 weeks, significant increases in subcutaneous fat in cheek: +0.54 g and upper limb: +145 g, but not lower limb |
| SALT [48]     | ATV/r + 3TC (n = 64) | 2 serious AEs, acute pyelonephritis, n = 1; traumatic bone fracture, n = 1 | Not reported                                                             | Not reported                                                          | Not reported                                                          | Not reported                                                          | Not reported                                                                |
|               | ATV/r + 2 NNRTI (n = 67) | 1 serious AE: toxicity due to drugs of abuse, n = 1 | Not reported                                                             | Not reported                                                          | Not reported                                                          | Not reported                                                          | Not reported                                                                |
| PI/r + NNRTI  | A5116 [50,87] | EFV + LPV/r (n = 118) | No difference in time to grade 3 or 4 AEs. Trend towards greater rate of first grade 3 or 4 laboratory abnormality in EFV + LPV/r arm, largely due to TG | Cholesterol increased with LPV/r + EFV compared to minimal changes with EFV + NRTI. Non-HDL cholesterol increased with LPV/r + EFV and decreased with EFV + NRTI. HDL increased in both groups. Greater increases in TG with LPV/r + EFV | Not reported                                                          | 48 weeks: no significant change for either group for lumbar or hip BMD or bone markers (osteocalcin and NTX) | Not reported                                                                |
|               | NEKA [51]   | LPV/r + NVP (n = 16) | Proportion of patients with AEs was similar between arms. GI symptoms were most frequently reported | By week 48, TC, HDL, and TG increased by 14%, 11%, and 56%, respectively | Not reported                                                          | Two patients had marked improvement in peripheral lipoatrophy         | Two patients saw improvement in peripheral lipoatrophy                     |
|               |             | LPV/r + 2 NRTIs (n = 15) | By week 48, TC, HDL, and TG increased by 13%, decreased by 11%, and increased by 18%, respectively | Not reported                                                          | Not reported                                                          | Two patients saw improvement in peripheral lipoatrophy                     | (Continued)
No study thus far has been able to examine the impact of dual therapy on these outcomes in the long term. Key secondary endpoint findings from studies identified in this report are summarised in Tables 3 and 6.

Renal Markers

Renal impairment, which is occasionally observed among individuals with HIV infection, may be related to chronic HIV infection, underlying comorbidities such as diabetes or hypertension, the use of medications, or a combination of factors [9,56–58]. Cohort studies have demonstrated that cumulative exposure to some ARVs, for example, TDF, is associated with increased rates of chronic kidney disease or decreases in the estimated glomerular filtration rate (eGFR) [9,56,57]. Sparing such agents may help preserve renal function.

Few studies included in this report reported renal function as an outcome. In the PROGRESS trial [24], a significantly greater decrease in eGFR from baseline was noted with LPV/r + TDF/FTC therapy than with LPV/r + RAL (−7.33 mL/min vs −1.43 mL/min, respectively; \( P = 0.035 \)), potentially due to the presence of TDF. A similar result was observed in the NEAT 001 study [20], where a reduction in eGFR was significantly greater in the DRV/r + TDF/FTC arm compared with the DRV/r + RAL arm at week 96 (−3.8 vs +0.9 mL/min, respectively;
Creatinine clearance at 48 weeks in the A4001078 study \([26,28,30]\) was stable with 
ATV/r + MVC therapy, but decreased with ATV/r + TDF/FTC therapy; at week 96, 
creatinine clearance decreased by 5.5 mL/min and 18 mL/min with ATV/r + MVC and 
ATV/r + TDF/FTC, respectively. In the SPARE study \([42]\), there was no statistically 
significant difference between treatment groups in the number of patients who achieved a 
> 10\% improvement from baseline in eGFR with either DRV/r + RAL therapy or LPV/r + TDF/FTC. In ATLAS \([45–47]\), 
eGFR was statistically increased versus baseline with ATV/r + 3TC (Cockroft-Gault equation, 
+6 mL/min, \(P<0.001\) at 48 weeks; Modified Diet in Renal Disease equation, +15 mL/min, 
\(P<0.001\) at 96 weeks). In the Reliquet 2014 study \([52]\), serum creatinine improved in patients 
who switched to RAL + NVP therapy. The long-term clinical relevance of these statistical 
differences in renal parameters remains unexplored.

Changes in Lipid Parameters

Changes in lipid parameters could serve as markers for future cardiovascular disease (CVD), 
an important issue in the aging populations of patients with HIV \([9]\). Along with traditional 
risk factors, such as smoking, some ARV agents have been associated with CVD \([13,59–61]\). 
Although NRTI-sparing dual therapy regimens may potentially improve lipid profiles and 
hence CVD risk, this question must be evaluated prospectively in the context of Framingham 
risk. Although the third agent included in triple therapy regimens may contribute to this risk, 
triple therapy regimens containing TDF tend to have more favourable lipid profiles compared 
with non-TDF regimens \([18,19,21,23,24,34,36,37,44,50,62]\). With the exception of the RADAR 
study (DRV/r + RAL), across the studies identified here, lipid abnormalities, especially eleva-
tions in triglyceride levels, were more frequent with dual therapy in CCTG 589, PROGRESS, 
KITE (all LPV/r + RAL), ACTG A5262 (DRV/r + RAL), ACTG 5142 and A5116 (both LPV/r 
+ EFV) \([18,19,21,23,24,36,37,44,50]\). However, in the VEMAN (LPV/r + MVC) and SPAR-
tAN (ATV + RAL) studies, the metabolic profile was found to be fairly stable between dual 
and triple therapy regimens \([16,27,29]\). In BMS-121 \([35]\), the higher ATV dose was associated 
with a greater change in fasting triglycerides. The implications of these changes for CVD risk 
are uncertain. Interestingly, the positive impact of NVP on lipid profiles was maintained when 
used in combination with LPV/r \([51]\). Investigators postulated that the improved atherogenic 
profile of LPV/r + NVP therapy among ARV-experienced, virologically suppressed patients 
could help lower the risk of cardiovascular events \([51]\). In the Reliquet 2014 (RAL + NVP) and 
ROCnRAL ANRS157 (RAL + MVC) studies, ARV-experienced, virologically-suppressed 
patients experienced decreases in lipid parameters after the switch to dual therapy \([52,54]\).

Hyperbilirubinemia

Hyperbilirubinemia is frequently reported with ATV therapy. In some NRTI-sparing 
regimens, the rate of hyperbilirubinemia is increased, potentially limiting the use of ATV in dual therapy 
regimens \([16,26,30]\). However, total bilirubin levels were not elevated by ATV used in combi-
nation with 3TC in the ATLAS trial \([45,47]\).

Bone Health

Osteoporosis is common in aging populations, especially in postmenopausal women. Thus, it 
is disconcerting that increased rates of BMD loss are observed in patients with HIV \([63]\). The 
relative contributions of HIV or its therapy to these observations remains uncertain. As has 
been noted in a number of recent studies, there is a decline in BMD of 2\% to 6\% with the initia-
tion of ARV therapy \([64]\). This has been found to be more marked in those regimens in which 
TDF is included \([65,66]\). Because HIV treatment is continued over the long-term, the
implications for bone health are worrisome. Few studies identified in this analysis examined the effect of dual therapy regimens on BMD.

PROGRESS [24] evaluated the change in BMD through 96 weeks and markers of bone turnover. The mean change from baseline in BMD was −2.48% for the LPV/r + TDF/FTC arm compared with an increase of 0.68% for the LPV/r + RAL arm (P<0.001). Bone turnover markers C-terminal telopeptide (CTX) and osteocalcin increased in both groups to week 96, with greater increases in the LPV/r + TDF/FTC arm. Early changes in bone turnover markers were associated with a >5% BMD decrease at week 96, and increases at 4 weeks in CTX were associated with clinically significant bone loss. TDF had a greater impact on bone turnover and was associated with a higher incidence of clinically significant bone loss compared with RAL in combination with LPV/r. Similar positive findings on bone markers were observed in ATLAS, where there was a trend toward increased lumbar spine vertebrae 2 and 4 BMD in the ATV/r + 3TC arm [47]. The ROCnRAL study [67] noted a mean increase in BMD during a 26-week evaluation period, corresponding to an estimated increase of 2% per year. Although these data provide evidence that measurement of bone markers may be predictive of changes in BMD and may be useful for biotherapeutic agent evaluation, caution is warranted because of the small number of study subjects, the less specific imaging used, and the wide variation in bone marker measures.

Body Fat Redistribution

Lipoatrophy has frequently been associated with NRTIs; previous studies have shown that patients switched from zidovudine (AZT) and stavudine (d4T) experience improvements in peripheral fat. Therefore, a regimen that spares one or more NRTIs may improve or prevent lipoatrophy. However, compared with earlier NRTIs, the rate of lipoatrophy with newer NRTIs (eg, TDF and abacavir) appears to be low, making it unclear whether NRTI-sparing regimens will have much clinical impact. In the studies examined here, an increase in limb fat was observed in NRTI-sparing regimens compared with triple therapy regimens, both in ARV-naive and virologically suppressed patients [25,36,45,50].

Discussion

A total of 29 studies that evaluated the effectiveness of novel dual therapy regimens were summarised in ARV-naive (16 studies) or ARV-experienced, virologically suppressed patients (13 studies). They provide preliminary, short-term insights into the potential of dual therapy regimens for achieving and maintaining adequate virologic suppression in these populations. Whether long-term viral suppression and reduced toxicity will be achieved and maintained remains unclear. Given the small patient numbers and short durations of most of the existing studies, it remains unknown to what extent resistance will develop upon failure of a particular regimen, or if re-suppression will be possible with a switch or intensification of therapy. Certain dual therapy combinations seem to have insufficient efficacy or safety profiles to be recommended as alternative options to current standard of care, specifically in ARV-naive patients: ATV 300 mg BID + RAL 400 mg BID due to high rates of severe bilirubinaemia [16], DRV/r 800/100 mg QD + RAL 400 mg BID in patients with CD4 counts <200 cells/μL [19], DRV/r 800/100 mg + MVC 150 mg QD due to inferior efficacy [31], and LPV/r 533/133 mg BID + EFV 600 mg QD due to poor tolerability [36,37]. Long-term studies evaluating efficacy, safety, adherence, pill burden, and cost-effectiveness are required to more completely understand the clinical value of other dual therapy approaches.

Because they were randomised and sufficiently powered to demonstrate noninferiority of the viral response at 48 weeks in the dual therapy arm compared with triple drug therapy
comprising a PI combined with 2 NRTIs, the NEAT 001 study, which compared DRV/r + RAL with DRV/r + TDF/FTC, the PROGRESS study, which compared LPV/r + RAL with LPV/r + TDF/FTC, and the GARDEL study, which compared an ARV-sparing regimen of LPV/r + 3TC with triple therapy, provide the most definitive evidence to date. NEAT 001 and PROGRESS assessed virologic efficacy up to 96 weeks [20,23,24], and all three studies found potential signals of reduced toxicity [23,24,34]. The GARDEL trial is further strengthened by the larger sample size, including a reasonable percentage of patients with a higher baseline viral load. To date, however, the findings of these studies have not been confirmed in second independent, adequately powered studies. In addition, no dual therapy regimens have been directly compared with each other in prospective, randomised controlled trials. As such, no definitive statement can be made regarding the dual therapy treatment strategy that would achieve the best virologic efficacy and safety outcomes in HIV-infected patients. In rare situations where NRTIs cannot be used owing to transmitted resistance or toxicity, the combinations of LPV/r + 3TC, LPV/r + RAL, or DRV + RAL could be considered as alternative options in treatment-naive patients.

Because some studies have suggested that TDF use is linked to renal injury [68,69] and an increased cardiovascular risk may be associated with ABC (although this remains controversial) [70–74], avoiding their use in certain patients may be prudent. According to current treatment guidelines, dual therapy with LPV/r + 3TC, LPV/r + RAL, or DRV + RAL can be considered when regimens containing ABC or TDF are not recommended or are contraindicated because of patient comorbidities, such as the presence of cardiovascular risk factors or pre-existing renal disease and a positive HLA-B*5701 test [2–4].

Carr et al [75] have cautioned that, although virologic noninferiority is an essential endpoint for simplification studies, it should not be the only endpoint, as virologic noninferiority alone is not a benefit. The disadvantages of existing ARV regimens, with respect to AEs, quality of life, cost, or other effects can only be addressed in a simplification study if the disadvantage is important, if the entry criteria are well-defined, and if there is adequate recruitment of at-risk participants to provide the statistical power that is required to yield clinically meaningful results. Furthermore, a clinically relevant endpoint is exponentially more meaningful than, for example, a statistically significant change in a laboratory parameter.

Unfortunately, most of the studies cited in this report have not adequately addressed the potential short- and long-term AEs with dual therapy regimens or demonstrated that the newer strategies provide important clinical benefits or are cost-effective in the long term. Taken as a whole, the potential benefits of dual therapy regimens for some organ systems (eg, kidney and bone) must be balanced against potential detriments in others (eg, CVD). Further, any negative effects of treatment may necessitate additional monitoring or treatment (eg, lipid-lowering agents). Finally, medication-related changes in lipids and other markers must be considered in the context of traditional risk factors on disease outcomes (ie, smoking) in aging HIV-positive populations [76,77]. This information will be critical before dual therapy regimens gain widespread use.

Implementation of a dual therapy regimen requires consideration of potential drug–drug interactions with other agents used as part of the ARV regimen, as well as other prescription and over-the-counter drugs. For example, because of effects mediated through cytochrome P450 metabolism, coadministration of NVP or MVC with certain PIs or other classes of drugs (eg, some NNRTIs, antifungals, antivirals, and antibiotics) can affect the plasma concentration of both agents; thus, coadministration may not be recommended or dose adjustments may be required [78,79]. Before initiation of an ARV regimen in the individual patient, evaluation of concomitant medication use and pertinent prescribing information, as well as other available resources [80], should be consulted to assess for any potential drug–drug interactions.
Limitations of this review include the restriction of eligible trials to those that evaluated dual therapy regimens in either ARV-naive or ARV-experienced, virologically suppressed patients. An examination of studies that assess the ability of dual therapy regimens to provide virologic suppression in ARV-experienced patients with VF (salvage therapy) [81,82] were beyond the scope of this report. Furthermore, patient subgroups, such as individuals with hepatitis C virus coinfection, were not examined, nor were study results stratified by age or gender. The effectiveness of dual therapy regimens in ARV-naive patients with baseline HIV-1 RNA levels >100,000 copies/mL is inadequately investigated in most of the studies reported. Therefore, careful interpretation of the findings is warranted. An evaluation of the effectiveness of dual therapy regimens in diverse patient population is also required. A potential concern with the use of dual therapy is the persistence of viral replication in reservoir sites such as the central nervous system (CNS) [83,84]. The evaluation of dual therapy regimens regarding penetration and effectiveness in potential reservoir sites, and specifically, CNS viral escape and the predictive value of CNS penetration effectiveness scores, requires further study.

Preliminary data from some studies are encouraging; however, it is not currently possible to recommend widespread adoption of novel dual therapy regimens. Future trials demonstrating adequate long-term efficacy and safety are required before dual therapy regimens can be incorporated into routine clinical practice for ARV-naive and ARV-experienced, virologically suppressed patients. Other dual therapy regimens that do not include a boosted PI are currently being investigated, and initial results show promise. For example, the exploratory proof-of-concept study using dolutegravir and lamivudine in ARV-naive subjects (PADDLE) showed no virologic failure in 20 patients after 24 weeks of therapy [85]. Another recent study conducted in ARV-experienced, virologically suppressed patients (LATTE) reported positive results using a dual regimen of an integrase inhibitor, cabotegravir, with rilpivirine [86]. Results from additional studies could lead to a shift in the treatment paradigm for HIV.

Supporting Information

S1 PRISMA Checklist. PRISMA checklist.

(DOC)

Acknowledgments

We thank Sandra Blitz for her review of the data searches and summaries. Medical editing support was provided by John E. Fincke, PhD, and Daniel McCallus, PhD, at Complete Publication Solutions, LLC; this support was sponsored by AbbVie Inc.

Author Contributions

Analyzed the data: JGB JBA MJG JG PC JVW SW. Wrote the paper: JGB JBA MJG JG PC JVW SW.

References

1. Vella S, Schwartlander B, Sow SP, Eholie SP, Murphy RL (2012) The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 26: 1231–1241. doi:10.1097/QAD.0b013e32835521a3 PMID: 22706009

2. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents (2015) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed: 22 July 2015.
3. European AIDS Clinical Society (2014) Guidelines: Clinical management of treatment of HIV infected adults in Europe. version 7.1. Available: http://www.eacsociety.org/files/guidelines_english_71_141204.pdf. Accessed: 22 July 2015.

4. Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenyi A, Benson CA, et al. (2014) Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312: 410–425. doi: 10.1001/jama.2014.8722 PMID: 25038359

5. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. (1998) Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 339: 1261–1268. PMID: 9791141

6. Pialoux G, Raffi F, Brun-Vezinet F, Meffredy V, Flandre P, Gastaut JA, et al. (1998) A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 339: 1269–1276. PMID: 9791142

7. Rejers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, et al. (1998) Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 352: 185–190. PMID: 9683207

8. McCutchan JA, Wu JW, Robertson K, Koletar SL, Ellis RJ, Cohn S, et al. (2007) HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 21: 1109–1117. PMID: 17502721

9. Salter ML, Lau B, Go VF, Mehta SH, Kirk GD (2011) HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis 53: 1256–1264. doi: 10.1093/cid/cir673 PMID: 21976463

10. Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, et al. (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43: 566–571. PMID: 14981616

11. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V (2010) Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ: c4986. doi: 10.1136/bmj.c4986 PMID: 20884968

12. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B (2010) Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ: c4249. doi: 10.1136/bmj.c4249 PMID: 20884966

13. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. (2008) First-line RAL + DRV/r is non-inferior to TDF/FTC + DRV/r: the NEAT001/ANRS143 randomised trial. 21st Conference on Retroviruses and Opportunistic Infections. 2014 March 3–6; Boston, MA.

14. Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. (2011) Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One 6: e22003. doi: 10.1371/journal.pone.0022003 PMID: 21811554

15. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J (2006) How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc 94: 130–136. PMID: 16636704

16. Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, et al. (2012) A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clin Trials 13: 119–130. doi: 10.1310/hct1303-119 PMID: 22592092

17. Bedimo R, Drechsler H, Turner D, Moore T, Ghormley J, Jain M, et al. RADAR study: Raltegravir combined with boosted darunavir has similar safety and antiviral efficacy as tenofevir/eremiticabine combined with boosted darunavir in antiretroviral-naive patients. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

18. Bedimo R, Drechsler H, Cутrell J, Jain M, Farukhi I, Castanon R, et al. RADAR study: week 48 safety and efficacy of RALTegravir combined with boosted DARunavir compared to tenofevir/eremiticabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 2013 June 30-July 3; Kuala Lumpur, Malaysia.

19. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, et al. (2011) Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 25: 2113–2122. doi: 10.1097/QUA.0b013e32834bbaa9 PMID: 21857490

20. Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, et al. First-line RAL + DRV/r is non-inferior to TDF/FTC + DRV/r: the NEAT001/ANRS143 randomised trial. 21st Conference on Retroviruses and Opportunistic Infections. 2014 March 3–6; Boston, MA.

21. Bowman V, Rieg G, Jain S, Goicoechea M, Dube M, Kerkar S, et al. 48 week results of a pilot randomized study of an nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen of raltegravir (RAL) + lopinavir/ritonavir (LPV/r) versus efavirenz/tenofevir disoproxil fumarate/eremiticabine (EFV/TDF/
FDC in antiretroviral-naive patients: CCTG 589. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

22. Qaqish R, Trinh R, Tian M, Fredrick L, Podsadecki T, Norton M, et al. Bone mineral density (BMD) analysis in antiretroviral (ART)-naive subjects taking lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) for 96 weeks in the PROGRESS study. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

23. Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, et al. (2011) Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the PROGRESS study, 48-week results. HIV Clin Trials 12: 255–267. doi: 10.1310/hct1205-255 PMID: 22180523

24. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, et al. (2013) Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses 29: 256–265. doi: 10.1089/AID.2011.0275 PMID: 22730829

25. van Wyk J, Domingo P, Fredrick L, Tian M, Saget B, Trinh R, et al. Body fat distribution changes after 96 weeks of therapy with lopinavir/ritonavir (LPV/r) plus raltegravir (RAL) compared with LPV/r plus tenofovir/emtricitabine (TDF/FTC) in antiretroviral (ARV)-naive, HIV-1-infected subjects from the PROGRESS study. 13th European AIDS Conference. 2011 October 12–14; Belgrade, Serbia.

26. Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, et al. 48-week results of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF) + ATV/r in treatment-naive patients infected with R5 HIV-1 (Study A4001078). 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

27. Nozza S, Galli L, Chiappetta S, Antinori A, Tommasi C, Di Pietro M, et al. (2012) Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTI-sparing regimen for HIV-infected naive patients: 48-weeks final results. J Int AIDS Soc 15 (suppl 4): 18232.

28. Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, et al. Once-daily maraviroc in combination ritonavir-boosted atazanavir in treatment-naive patients infected with CCR5 tropic HIV-1 (study A4001078): 96 week results. XIX International AIDS Conference. 2012 July 22–27; Washington, DC.

29. Nozza S, Galli L, Antinori A, Di Pietro M, Tommasi C, Zaccarelli M, et al. Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTIs-sparing regimen for naive patients: preliminary 48-weeks results. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

30. Portsmouth S, Craig C, Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, et al. 48-week results of dual-therapy regimen of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF) + ATV/r in treatment-naive (TN) patients infected with CCR5-tropic H (Study A4001078). 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

31. Taiwo B, Swindells S, Berzins BI, Acosta EP, Ryscavage P, Lalezari J, et al. Week 48 results of the maraviroc plus darunavir/ritonavir study (MIDAS) for treatment-naive patients infected with R5-tropic HIV-1: XIX International AIDS Conference. 2012 July 22–27; Washington, DC.

32. Stellbrink HJ, Pulik P, Szlakij V, Murphy D, Lazzarin A, Portilla J, et al. Maraviroc (MVC) once daily with darunavir/ritonavir (DRV/r) compared to tenofovir/emtricitabine (TDF/FTC) with DRV/r: 48-Week results from MODERN (Study A4001095). 20th International AIDS Conference. 2014 July 20–25; Melbourne, Australia.

33. Andrade R, Villarreal-Williams E, Mall M, Shillington A, Pasley M, Trinh R, et al. A pilot study: lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) as dual agents in antiretroviral (ARV) naive HIV-infected subjects (the LOREDA study). 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

34. Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, et al. (2014) Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 14: 572–580. doi: 10.1016/S1473-3099(14)70736-4 PMID: 24783988

35. Ward D, Bush L, Thiry A, Guo T, Parks D, Jemsek J, et al. Atazanavir/ritonavir (ATV/RTV) and efavirenz (EFV) NRTI-sparing regimens in treatment-naive adults. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 2006 Sept 27–30; San Francisco, CA.
38. Ruane PJ, Wolfe PR. Dual maintenance therapy with raltegravir 400 mg BID with atazanavir 400 mg QD in patients with no prior PI resistance and intolerance to other ATV regimens: follow up report. International Conference on Antimicrobial Agents and Chemotherapy 2010 September 12–15; Boston, MA.

39. Harris M, Cote H, Ochoa C, Allavena C, Negredo E, Thorne A, et al. (2009) A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients. J Acquir Immune Defic Syndr 50: 335–337. doi: 10.1097/QAI.0b013e3181938f0c PMID: 19479079

40. Cohen C, Green J, Olivet H, Khanlou H, Burman W, Corales R, et al. (2012) A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r vs. RAL BID + ATV BID. J Int AIDS Soc 15 (suppl 4): 18279.

41. Ruane PJ, Wolfe PR. Dual maintenance therapy with raltegravir 400 mg BID with atazanavir 400 mg QD in patients with no prior PI resistance and intolerance to other ATV regimens: follow up report. International Conference on Antimicrobial Agents and Chemotherapy 2010 September 12–15; Boston, MA.

42. Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, et al. (2013) Switching tenofovir/emtricitabine plus lopinavir/ritonavir to raltegravir plus Darunavir/ritonavir in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One 8: e73639. doi: 10.1371/journal.pone.0073639 PMID: 23951362

43. Calza L, Vanino E, Colangeli V, Manfredi R, Borderi M, Puggioli C, et al. Treatment simplification to atazanavir/ritonavir plus lamivudine qd in patients on two NRTIs plus atazanavir/ritonavir with optimal virologic control: 48 weeks safety and efficacy results from a pilot study (atazanavir and lamivudine simplification study). 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

44. De Luca A, Doino M, Fabbiani M, Bracciale L, Ciccarelli N, Colafigli M, et al. Treatment simplification to atazanavir/ritonavir plus lamivudine qd in patients on two NRTIs plus atazanavir/ritonavir with optimal virologic control: 96 weeks follow-up of a pilot study (atazanavir and lamivudine simplification study, ATLAS). XIX International AIDS Conference 2012 July 22–27; Washington, DC.

45. Fabbiani M, Di Giambenedetto S, Doino M, Farina S, Mondi A, Bianco C, et al. Evolution of bone mineral density and metabolism and of subcutaneous fat in patients enrolled in the atazanavir/r + lamivudine simplification study (ATLAS). 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

46. Fabbiani M, Colafigli M, Farina S, D’Avino A, Mondi A, Bianco C, et al. Treatment simplification to atazanavir/ritonavir plus lamivudine qd in patients on two NRTIs plus atazanavir/ritonavir with optimal virologic control: 96 weeks follow-up of a pilot study (atazanavir and lamivudine simplification study, ATLAS). XIX International AIDS Conference 2012 July 22–27; Washington, DC.

47. Fabbiani M, Di Giambenedetto S, Doino M, Farina S, Mondi A, Colafigli M, et al. Evolution of bone mineral density and metabolism and of subcutaneous fat in patients enrolled in the atazanavir/r + lamivudine simplification study (ATLAS). 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 July 17–20; Rome, Italy.

48. Perez-Molina JA, Rivero A, Pasquau J, Rubio R, Estebanez M, Sanz J, et al. Safety and efficacy of switching to dual therapy (atazanavir/ritonavir + lamivudine) vs. triple therapy (atazanavir/ritonavir _ two nucleos(t)ides) in patients on virologically stable antiretroviral therapy: 24-week interim analysis from a randomized clinical trial (SALT study). 14th European AIDS Clinical Society Conference. 2013 October 16–19; Brussels, Belgium.

49. Amaiz JA (2013) Study to evaluate the activity and tolerability of lopinavir/ritonavir and lamivudine bitherapy in HIV patients with viral suppression (OLE) (NCT01471821). Available: https://www.clinicaltrials.gov/ct/show/NCT01471821?term=OLE+hiv&rank=1. Accessed: 22 July 2015.

50. Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, et al. (2007) Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS 21: 325–333. PMID: 17255739

51. Negredo E, Molto J, Burger D, Cote H, Miro O, Ribaltà J, et al. (2005) Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J Acquir Immune Defic Syndr 38: 47–52. PMID: 15609524
52. Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, Andre-Garnier E, et al. (2014) Nevirapine-raltegravir combination, a NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients. Antiviral Therapy 19: 117–123.

53. Calin R, Valantin M-A, Simon A, Paris L, Tubiana R, Schneider L, et al. Raltegravir/etravirine dual therapy as a virologically safe treatment option in suppressed HIV-1-infected patients without previous NNRTI failure. 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 2013 June 30–July 3; Kuala Lumpur, Malaysia.

54. Katlama C, Assoumou L, Valantin M-A, Duvivier C, Soulie C, Chabalais L, et al. Maraviroc plus raltegravir dual therapy in aviremic HIV infected patients with lipodystrophy: results from the ROCnRAL ANRS 157 study. 20th Conference on Retroviruses and Opportunistic Infections. 2013 March 3-6; Atlanta, GA.

55. Cotte L, Durant J, Brochier C, Andre P, Cottalorda J, Pradat P, et al. Safety and efficacy of a maraviroc-raltegravir combination following a 6 month induction phase with maraviroc-raltegravir-emtricitabine in naive HIV-1 infected patients with CCR5 virus: interim analysis of the No Nuc No Boost study. 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 2013 June 30-July 3; Kuala Lumpur, Malaysia.

56. Dazo C, Fahey P, Puls R, Winston A, Boesecke C, Avihingsanon A, et al. Small but significant and non-progressive decline in GFR observed in therapy-naive HIV+ subjects commencing r/ATV, compared to either EFV or ZDV/ABC with TDF/FTC after 48 weeks: a randomized controlled study. 18th Conference on Retroviruses and Opportunistic Infections. 2011 February 27-March 2; Boston, MA.

57. Kirk O, Mocroft A, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Chronic kidney disease and exposure to ART in a large cohort with long-term follow-up: the EuroSIDA Study. 17th Conference on Retroviruses and Opportunistic Infections. 2010 February 16–19; San Francisco, CA.

58. Moffat A, Kirk O, Reiss P, De Wit S, Sediack D, Beniowski M, et al. (2010) Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24: 1667–1678. doi: 10.1097/QAD.0b013e328339fe53 PMID: 20523203

59. Monforte AD, Reiss P, Ryom L, El-Sadr W, De Wit S, et al. ATV-containing ART is not associated with an increased risk of cardio- or cerebro-vascular events in the D:A:D study. 19th Conference on Retroviruses and Opportunistic Infections. 2012 March 5–8; Seattle, WA.

60. Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22: F17–24. doi: 10.1097/QAD.0b013e32830fe35e PMID: 18753925

61. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. (2010) Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201: 318–330. doi: 10.1086/649897 PMID: 20039804

62. Achhra AC, Amin J, Hoy J, Tanuma J, Sirisanthana T, Nolan D, et al. (2012) Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia. AIDS Res Treat 2012: 246280. doi: 10.1155/2012/246280 PMID: 22675613

63. Yin MT, Zhang CA, McMahon DJ, Ferris DC, Irani D, Colon L, et al. (2012) Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab 97: 554–562. doi: 10.1210/jc.2011-2197 PMID: 22090266

64. Walker Harris V, Brown TT (2012) Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 205 Suppl 3: S391–398. doi: 10.1093/infdis/js199 PMID: 22577213

65. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191–201. PMID: 15249568

66. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203: 1791–1801. doi: 10.1093/infdis/jir188 PMID: 21606537

67. Katlama C, Assoumou L, Valantin MA, Soulie C, Duvivier C, Chabrais L, et al. (2014) Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipo hypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother 69: 1648–1652. doi: 10.1093/jac/dkt536 PMID: 24535278

68. Hall AM, Hendry BM, Nitsch D, Connolly JO (2011) Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 57: 773–780. doi: 10.1053/j.ajkd.2011.01.022 PMID: 21435764
69. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et al. (2013) Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 207: 1359–1369. doi:10.1093/infdis/jit043 PMID: 23382571

70. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. (2011) Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 25: 1993–2004. doi:10.1097/QAD.0b013e328349c6ee PMID: 21716077

71. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG (2011) Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 25: 1289–1298. doi:10.1097/QAD.0b013e31826f993c PMID: 21516027

72. Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, et al. (2015) Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis 61: 445–452. doi: 10.1093/cid/civ316 PMID: 25908684

73. Ding X, Andracca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. (2012) No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 61: 441–447. doi:10.1097/QAI.0b013e31826f993c PMID: 22932321

74. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olikin I, Sundaram V, et al. (2013) Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One 8: e59551. doi:10.1371/journal.pone.0059551 PMID: 23555704

75. Carr A, Hoy J, Pozniak A (2012) The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior? PLoS Med 9: e1001240. doi:10.1371/journal.pmed.1001240 PMID: 22815652

76. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. (2003) Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1179–1193. PMID:12819520

77. National Institutes of Health (2011) What are coronary heart disease risk factors? Available:http://www.nhlbi.nih.gov/health/health-topics/topics/hd/. Accessed: 22 July 2015.

78. VIRAMUNE (nevirapine). Full Prescribing Information, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 2014.

79. SELZENTRY (maraviroc). Full Prescribing Information, ViV Healthcare, Research Triangle Park, NC, 2015.

80. New York State Department of Health AIDS Institute HIV Drug-Drug Interactions. Available: http://www.hivguidelines.org/clinical-guidelines/adults/hiv-drug-drug-interactions. Accessed: 22 July 2015.

81. Burgos J, Crespo M, Falco V, Curran A, Imaz A, Domingo P, et al. (2012) Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-infected patients on a failing antiretroviral regimen. J Antimicrob Chemother 67: 1453–1458. doi:10.1093/jac/dks057 PMID: 22376861

82. Capetti AF, Piconi S, Landonio S, Rizzato G, Perno CF (2009) Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? J Acquir Immune Defic Syndr 50: 233–234. doi: 10.1097/QAI.0b013e3181818c7e PMID: 19155770

83. Spudich SS, Ances BM (2013) Neurologic complications of HIV infection: highlights from the 2013 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med 21: 100–108. PMID: 23981597

84. Peluso MJ, Spudich S (2014) Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics. Curr HIV/AIDS Rep 11: 353–362. doi:10.1007/s11904-014-0223-9 PMID: 25063356

85. Figueroa M, Sued O, Patterson P, Gun A, Rolón M, Cahn P, Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naïve patients: First results of the PADDLE trial. 15th European AIDS Conference. 2015 October 21–24; Barcelona, Spain.

86. Margolis D, Brinon C, Smith G, de Vente J, Hagens D, Griffith S, et al. Cabotegravir and rilpivirine as two-drug oral maintenance therapy: LATTE week 96 results. Conference on Retroviruses and Opportunistic Infections, 2015 February 23–26.

87. Tebas P, Zhang J, Yarasheeki K, Evans S, Fischl MA, Shvitz A, et al. (2007) Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 45: 193–200. PMID: 17527093